<rss version='2.0'>

                    <channel>

                    <title><![CDATA[Lymphoma]]></title>

                    <link>https://www.benthamscience.com</link>

                    <description>

                    RSS Feed for Disease Wise Article | BenthamScience

                    </description>

                    <generator>EurekaSelect (+http://eurekaselect.com)</generator>

                    <pubDate>Fri, 12 Jun 2026 20:14:39 +0000</pubDate>

                    <image>

                    <title><![CDATA[Lymphoma]]></title>

                    <url>https://www.benthamscience.com</url>

                    <link>https://www.benthamscience.com</link>

                    </image><item><title><![CDATA[Treatment of Refractory p53 Mutation Large B-cell Lymphoma with Daratumumab and Venetoclax Followed by CAR-T Cell Therapy: Case Report and Animal Study]]></title><link>https://www.benthamscience.comarticle/137662</link><description><![CDATA[<p>Background: The tumor burden before chimeric antigen receptor T (CAR-T) cell therapy was one of the critical factors affecting the prognosis of lymphoma. It was a challenge to effectively reduce the tumor burden of relapsed/refractory large B-cell lymphoma with p53 mutation. </p> <p> Objective: Here, we have presented a case of relapsed/refractory large B-cell lymphoma with p53 mutation being controlled by the treatment with daratumumab and venetoclax, followed by CAR-T cell therapy. </p> <p> Case Presentation: The patient was a 56-year-old female who was diagnosed with relapsed/ refractory diffuse large B cell lymphoma (DLBCL) transformed from follicular lymphoma. The patient was treated with daratumumab, venetoclax, and GEMOX (gemcitabine and oxaliplatin) under the guidance of high-throughput drug sensitivity analysis. We used a CD38 positive lymphoma cell line with p53 mutation to construct tumor models for validating the anti- lymphoma effect of the combination therapy of daratumumab and venetoclax. </p> <p> Results: The patient achieved a complete metabolic response after treatment with daratumumab, venetoclax, and GEMOX. Then, she further achieved a complete molecular response after she subsequently received CAR-T cell therapy, and she has been living without a lymphoma recurrence. The results from the animal study showed that the combination of daratumumab and venetoclax could significantly enhance the antitumor effect on CD38-positive lymphoma with p53 mutation. </p> <p> Conclusion: The results from our successful case and animal experiments provide new avenues for the treatment of relapsed/refractory large B-cell lymphoma with p53 mutation. Further clinical trials are reuqired to treat CD38-positive lymphoma with the combination of daratumumab and venetoclax.</p>]]></description> </item><item><title><![CDATA[Frequency of Cancer Associated with Children and Adolescents]]></title><link>https://www.benthamscience.comarticle/132834</link><description><![CDATA[<P>Background: More than 175,000 new cases of cancer in children are diagnosed every year worldwide. <P> This study aimed to investigate the recorded cancer frequency in children and adolescents in Isfahan Province, Iran. <P> As one of the main reasons for death among children and adolescents is reported as cancer with different prevalence worldwide, therefore, reporting the occurrence of cancers in this population is crucial. <P> Methods: Information from the years between 2013 to 2015 related to the Surveillance, Epidemiology, and End Results; (SEER) was collected from the Isfahan Cancer Registry. The cancer sites studied were defined according to the International Classification of Diseases and recorded by related topography codes. <P> Results: Among all 30,465 registered cancers, there were 582 cases (2%) of cancer, including 57% of children and 43% of adolescents. The mean ± SD age of patients was 11.5 ± 5.9 years (Min; 1, Max 19). The top four ranked cancers were (n=264; 45%) comprised of; 1) hematopoietic and reticuloendothelial system (n= 122), 2) secondary and unspecified malignant neoplasm of lymph nodes (n=56), 3) malignant neoplasm of the brain (n=43) 4), thyroid gland (n=43). Death-reported data was associated with 32% of the total population studied. The neoplasm was reported in 174 cases, which was associated with 95% death. <P> Conclusion: This frequency source of children and adolescents cancers could be used for health strategy. The observed variations in the frequency of different cancers require continuous monitoring and investigation. Therefore, plan of health-system should focus based on greater efforts toward advanced evidence-based drug therapy in Isfahan, Iran.</P>]]></description> </item><item><title><![CDATA[Fangchinoline, an Extract of the <i>Stephania tetrandra</i> S. Moore Root, Promoted
Oxidative Stress-induced DNA Damage and Apoptosis and Inhibited Akt
Signaling in Jurkat T Cells]]></title><link>https://www.benthamscience.comarticle/129426</link><description><![CDATA[<p>Background: Fangchinoline (Fan) is extracted from traditional Chinese medicine (called Fangji), or the root of Stephania tetrandra Moore. Fangji is well-known in Chinese medical literature for treating rheumatic diseases. Sjogren&#039;s syndrome (SS) is a rheumatic disease whose progression can be mediated via CD4+ T cell infiltration. <p> Objective: This study identifies the potential role of Fan in inducing apoptosis in Jurkat T cells. <p> Methods: First, we explored the biological process (BP) associated with SS development by performing a gene ontology analysis of SS salivary gland-related mRNA microarray data. The effect of Fan on Jurkat cells was investigated by analyzing the viability, proliferation, apoptosis, reactive oxygen species (ROS) production, and DNA damage. <p> Results: Biological process analysis showed that T cells played a role in salivary gland lesions in patients with SS, indicating the significance of T cell inhibition in SS treatment. Viability assays revealed that the half-maximal inhibitory concentration of Fan was 2.49 μM in Jurkat T cells, while the proliferation assay revealed that Fan had an inhibitory effect on the proliferation of Jurkat T cells. The results of the apoptotic, ROS, agarose gel electrophoresis, and immunofluorescence assays showed that Fan induced oxidative stress-induced apoptosis and DNA damage in a dosedependent manner. <p> Conclusion: These results indicate that Fan could significantly induce oxidative stress-induced apoptosis and DNA damage and inhibit the proliferation of Jurkat T cells. Moreover, Fan further enhanced the inhibitory effect on DNA damage and apoptosis by inhibiting the pro-survival Akt signal.</p>]]></description> </item><item><title><![CDATA[Molecular Insight into the Apoptotic Mechanism of Cancer Cells: An
Explicative Review]]></title><link>https://www.benthamscience.comarticle/137402</link><description><![CDATA[<P>Mitosis of somatic cells produces a daughter cell. Apoptosis, a naturally programmed cellular death mechanism, kills abnormal cells produced by mitosis. Cancer can develop when this equilibrium is disrupted, either by an upsurge in cell propagation or a reduction in tissue demise. Cancer therapy aims to cause cancer cells to die while inflicting little harm to healthy cells. This review of apoptotic mechanism processes improves our understanding of how certain malignancies begin and develop. The current cancer treatments can operate either by inducing apoptosis or causing direct cell damage. An insight into the resistance to apoptosis may explicate why malignancy treatments fail in some situations. New therapies grounded on our understanding of apoptotic processes are being developed to induce apoptosis of cancer cells while limiting the simultaneous death of normal cells. Various biological activities require redox equilibrium to function properly. <P> Antineoplastic medications that cause oxidative stress by raising ROS and blocking antioxidant mechanisms have recently attracted much interest. The rapid accumulation of ROS impairs redox balance and damages cancer cells severely. Here, we discuss ROS-instigating malignancy therapy and the antineoplastic mechanism used by prooxidative drugs.</P>]]></description> </item><item><title><![CDATA[A Review of the Dual Role of MicroRNA-21 in Cardiovascular Diseases: Risk
Factor or a Potential Therapeutic Target]]></title><link>https://www.benthamscience.comarticle/138046</link><description><![CDATA[Cardiovascular diseases (CVD) are the number one reason for morbidity and mortality in the modern world, and their incidence is increasing at an incredible pace. Increasing evidence has shown the significant functions of microRNAs in the cardiovascular system and has highlighted their potential application as a new era of diagnostic and therapeutic targets for CVD that can improve the prognosis and life expectancy of patients. Among more than 2,000 microRNAs, microRNA-21 (miR-21) is highly expressed in human hearts and has earned the interest of researchers as a potential biomarker in a wide range of common heart conditions. Here, we summarized recent research progress regarding the significant role of miR-21 in CVD, focusing on cardiotoxicity, heart arrhythmias, cardiomyopathies, and hypertension. Several signaling pathways (TGF-&#946;1/Smad2 signaling, FGFR1/FGF21/PPAR&#947;, NF-&#954;B/miR-21/SMAD7, miR-21/SPRY1/ERK/mTOR …) and molecular targets (BTG2, PDCD4, PTEN, STAT3…) were reported to be controlled, at least partially, by miR-21 and are linked to CVD pathogenesis. Most investigations highlighted miR-21 cardioprotective functions in heart injury, while some other studies showed that this miR is elevated in the serum/tissue of patients, promoting fibrosis and cardiac dysfunction. This dual role can be explained by the fact that miR-21 has multiple regulatory functions depending on the microenvironment, downstream signaling, and target genes, which indicates that cell-type-specific investigations should receive more attention. With further investigations, miR-21 can be considered a novel tailored therapy with favorable outcomes.]]></description> </item><item><title><![CDATA[Maprotiline Prompts an Antitumour Effect by Inhibiting PD-L1 Expression in
Mice with Melanoma]]></title><link>https://www.benthamscience.comarticle/135227</link><description><![CDATA[<p>Background: Research has revealed that the expression of PD-L1 is significantly upregulated in tumour cells and that the binding of programmed cell death protein 1 (PD-1) to programmed cell death 1 ligand 1 (PD-L1) inhibits the response of T cells, thereby suppressing tumour immunity. Therefore, blocking PD-L1/PD-1 signalling has become an important target in clinical immunotherapy. Some old drugs, namely, non-anticancer drugs, have also been found to have antitumour effects, and maprotiline is one of them. Maprotiline is a tetracyclic antidepressant that has been widely used to treat depression. However, it has not yet been reported whether maprotiline can exert an antitumour effect on melanoma. <p> Objective: This study aimed to investigate the antitumour efficacy of maprotiline in mice with melanoma. <p> Methods: In this study, female C57BL/6 mice were used to establish a tumour-bearing animal model. After treatment with maprotiline, the survival rate of mice was recorded daily. The expression of relevant proteins was detected by Western blotting, the proportion of immune cells was detected by flow cytometry, and the infiltration of immune cells in tumour tissue was detected by immunofluorescence staining. <p> Results: Maprotiline was found to inhibit the proliferation and migration of B16 cells while increasing cell apoptosis. Importantly, treatment with maprotiline decreased the expression of PD-L1 and increased the proportion of CD4+ T cells, CD8+ T cells, and NK cells in the spleen. It also increased the infiltration of CD4+ and CD8+ T cells in tumour tissue. <p> Conclusion: Our research findings suggest that maprotiline enhances the antitumour immune response in mouse melanoma by inhibiting PD-L1 expression. This study may discover a new PD-L1 inhibitor, providing a novel therapeutic option for the clinical treatment of tumours.</p>]]></description> </item><item><title><![CDATA[Peptides for Dual Targeting of ErbB1 and ErbB2: Blocking EGFR Cell
Signaling Transduction Pathways for Cancer Chemotherapy]]></title><link>https://www.benthamscience.comarticle/129787</link><description><![CDATA[Cancer is one of the most deadly diseases involving dysregulated cell proliferation. Chemotherapeutic drugs have serious drawbacks of nonspecific toxicity and drug resistance. Tyrosine kinases are a significant class of enzymes of protein kinases. The four members of the trans-membrane family of tyrosine kinase receptors known as the human epidermal growth factor receptors (EGFR), ErbB1/HER1, ErbB2/HER2/neu, ErbB3/HER3, and ErbB4/HER4, are overexpressed in many forms of cancer. These receptors are crucial for cell division, invasion, metastasis, angiogenesis, and uncontrolled activation of cancer cells. In this context, an attractive combination of anticancer drug targets is ErbB1 and ErbB2. Numerous cancer types exhibit overexpression of ErbB1 and ErbB2, which is linked to poor prognosis and causes resistance to ErbB1-targeted therapy. Further, it has been reported in recent years that the use of peptides as anticancer agents have the potential to circumvent the drawbacks of the currently used chemotherapeutic drugs. Among them, short peptides have several advantages when compared to small molecules. The present report reviews the importance of tyrosine kinases as targets for cancer, the role of peptides as therapeutic agents, and the investigations that have been carried out by earlier workers for targeting both ErbB1 and ErbB2 using therapeutic peptides.]]></description> </item><item><title><![CDATA[The Regulatory Mechanism of Hypoxia-inducible Factor 1 and its Clinical
Significance]]></title><link>https://www.benthamscience.comarticle/137225</link><description><![CDATA[Hypoxia-inducible factor (HIF) is a nuclear protein that plays a crucial role in oxygen homeostasis through its transcriptional activity and thousands of target gene profiles. Through transcriptional and post-transcriptional regulation, the downstream target genes of HIF can trigger multiple pathological responses in the body, including energy metabolism, cytopenia, and angiogenesis. There are three distinct subtypes of HIF: HIF-1, HIF-2, and HIF-3. HIF-1 is a significant regulator of the cellular response to hypoxia, and the balance between its production and degradation is critical for this response. As hypoxia is linked to several disorders, understanding HIF can open up novel avenues for the treatment of many diseases. This review describes the regulatory mechanisms of HIF-1 synthesis and degradation and the clinical significance of the hypoxia-inducible factor pathway in lung injury, kidney disease, hematologic disorders, and inflammation-related diseases.]]></description> </item><item><title><![CDATA[At the Crossroads of TNF &#945; Signaling and Cancer]]></title><link>https://www.benthamscience.comarticle/134363</link><description><![CDATA[Tumor necrosis factor-alpha (TNF&#945;) is a pleiotropic pro-inflammatory cytokine of the TNF superfamily. It regulates key cellular processes such as death, and proliferation besides its well-known role in immune response through activation of various intracellular signaling pathways (such as MAPK, Akt, NF-&#954;B, etc.) via complex formation by ligand-activated TNF&#945; receptors. TNF&#945; tightly regulates the activity of key signaling proteins via their phosphorylation and/or ubiquitination which culminate in specific cellular responses. Deregulated TNF&#945; signaling is implicated in inflammatory diseases, neurological disorders, and cancer. TNF&#945; has been shown to exert opposite effects on cancer cells since it activates prosurvival as well as anti-survival pathways depending on various contexts such as cell type, concentration, cell density, etc. A detailed understanding of TNF&#945; signaling phenomena is crucial for understanding its pleiotropic role in malignancies and its potential as a drug target or an anticancer therapeutic. This review enlightens complex cellular signaling pathways activated by TNF&#945; and further discusses its role in various cancers.]]></description> </item><item><title><![CDATA[IMPDH2 Positively Impacts the Proliferation Potential of Hepatoblastoma Cells
by Activating JunB Signaling Pathway]]></title><link>https://www.benthamscience.comarticle/138645</link><description><![CDATA[<P>Background: Amplification of inosine monophosphate dehydrogenase II, EC 1,1,1,205 (IMPDH2) has been reported in various cancers, which results in transformation and tumorigenicity. In our current work, we have explored the oncogenic properties and the underlying pathophysiology of IMPDH2 in hepatoblastoma (HB). <P> Methods: To investigate IMPDH2 expression in HB tissues and prognostic significance in HB patients, gene expression profiling interactive analysis (GEPIA) has been adopted. Immunohistochemistry has also helped to validate the protein expression of IMPDH2 in HB tissues. The effect of IMPDH2 overexpression or depletion on the proliferation of Hepatoblastoma cells in vitro has been evaluated by CCK8 assays and colony formation assays. Xenograft tumor growth of mice has been detected. Luciferase reporter assays have been conducted to determine the interaction of IMPDH2 and JunB, which was further asserted by pharmacological inhibition of JunB. <P> Results: IMPDH2 was highly expressed in HB tissues. Experimentally, the proliferation and colony formation of HuH6 cells were increased by IMPDH2 overexpression. Conversely, genetic inactivation of IMPDH2 impaired the proliferative efficiency and colony-forming rate of HepG2 cells. Besides, the luciferase reporter assay validated IMPDH2 overexpression to be associated with enhanced JunB transcriptional activity, while its activity was diminished in the case of IMPDH2 depletion. JunB inhibitor neutralized the IMPDH2-mediated increased phosphorylation of JunB. <P> Conclusion: Our findings, thus, suggest that IMPDH2 exhibits its oncogenic role in HB partially via JunB-dependent proliferation.</P>]]></description> </item><item><title><![CDATA[E2F1 Reduces Sorafenib’s Sensitivity of Esophageal Carcinoma Cells via
Modulating the miR-29c-3p/COL11A1 Signaling Axis]]></title><link>https://www.benthamscience.comarticle/130004</link><description><![CDATA[<P>Objective: Esophageal carcinoma (ESCA) is a common malignancy characterized by high morbidity and mortality. Our work managed to dissect the modulatory mechanism of E2F1/miR-29c-3p/COL11A1 in the malignant progression and sensitivity of ESCA cells to sorafenib. <P> Methods: Via bioinformatics approaches, we identified the target miRNA. Subsequently, CCK-8, cell cycle analysis, and flow cytometry were used to check the biological influences of miR-29c-3p on ESCA cells. TransmiR, mirDIP, miRPathDB, and miRDB databases were used as tools for the prediction of upstream transcription factors and downstream genes of miR-29c-3p. The targeting relationship of genes was detected via RNA immunoprecipitation and chromatin immunoprecipitation, which was further validated by dual-luciferase assay. Finally, in vitro experiments revealed the way E2F1/miR-29c-3p/COL11A1 affected sorafenib’s sensitivity, and in vivo experiments were used to verify the way E2F1 and sorafenib impacted ESCA tumor growth. <P> Results: miR-29c-3p, downregulated in ESCA, could suppress ESCA cell viability, arrest the cell cycle in the G0/G1 phase, and impel apoptosis. E2F1 was found to be upregulated in ESCA and it could abate the transcriptional activity of miR-29c-3p. COL11A1 was found to be a downstream target of miR-29c-3p to enhance cell viability, induce cell cycle arrest in S phase, and constrain apoptosis. Cellular and animal experiments together demonstrated that E2F1 abated the sorafenib’s sensitivity of ESCA cells via miR-29c-3p/COL11A1. <P> Conclusion: E2F1 affected the viability, cell cycle, and apoptosis of ESCA cells by modulating miR-29c-3p/COL11A1, and it attenuated the sensitivity of ESCA cells to sorafenib, shedding new light on the treatment of ESCA.</P>]]></description> </item><item><title><![CDATA[Targeting Mutant-p53 for Cancer Treatment: Are We There Yet?]]></title><link>https://www.benthamscience.comarticle/134511</link><description><![CDATA[<P>Background: Mutations in the TP53 gene are the most common among genetic alterations in human cancers, resulting in the formation of mutant p53 protein (mutp53). Mutp53 promotes proliferation, migration, invasion, and metastasis in cancer cells. Not only does the initiation of oncogenesis ensue due to mutp53, but resistance towards chemotherapy and radiotherapy in cancer cells also occurs. This review aims to summarise and discuss the oncogenesis of mutant p53 in cancer cells and introduce the various mutant p53 inhibitors currently being evaluated at the pre-clinical and clinical stages. Compounds that induce the wild-type conformation on the targeted p53 missense mutation, restore or enhance the DNA binding of mutant p53, and inhibit cancer cells' growth are highlighted. In addition, the progression and development of the mutant p53 inhibitors in clinical trials are updated. <P> Conclusion: The progress of developing a cancer treatment that may successfully and efficiently target mutant p53 is on the verge of development. Mutant p53 proteins not only initiate oncogenesis but also cause resistance in cancer cells to certain chemo or radiotherapies, further endorse cancer cell survival and promote migration as well as metastasis of cancerous cells. With this regard, many mutant p53 inhibitors have been developed, some of which are currently being evaluated at the pre-clinical level and have been identified and discussed. To date, APR-246 is the most prominent one that has progressed to the Phase III clinical trial.</P>]]></description> </item><item><title><![CDATA[Physalin B Reduces Tau Phosphorylation and Cell Apoptosis in HEK293 Cells
by Activating FoxO1]]></title><link>https://www.benthamscience.comarticle/133071</link><description><![CDATA[<P>Background: Physalin B (PB) is one of the main active compounds of Solanaceae plants, with a wide range of biological activities. PB reportedly has the potential to treat Alzheimer’s disease (AD). <P> Objective: In this study, we investigated the effect of PB on Tau phosphorylation and cell apoptosis using Tau-expressing HEK293 cells (HEK293/Tau) as a cellular model. <P> Methods: The optimum concentration of PB to treat HEK293/Tau cells was determined using the CCK-8 assay. Additionally, the expression of FoxO1, Tau-5, p-Tau (T231, S262, and S404), ERK, p-ERK, GSK-3&#946;, and p-GSK-3&#946; was detected using western blotting to determine the effect of PB on Tau phosphorylation. The apoptosis rate was detected using flow cytometry, and the expression of Bax and Bcl-2 was detected using western blotting and verified using real-time quantitative polymerase chain reaction (RT-qPCR). Moreover, cells were transfected with FoxO1 siRNA to downregulate FoxO1 expression, and the expression of the above-mentioned proteins was detected to verify the effect of PB on Tau phosphorylation and cell apoptosis. <P> Results: After 24 h of PB treatment, the phosphorylation levels of Tau at S404, S262, and T231 sites decreased significantly, and the activities of GSK-3β and ERK were inhibited. PB also reduced cell apoptosis by reducing the expression of Bax and increasing the expression of Bcl-2. In addition, PB decreased Tau phosphorylation and cell apoptosis by upregulating FoxO1. <P> Conclusion: The natural compound PB exhibited a protective effect in the AD cell model by increasing FoxO1 expression and reducing Tau phosphorylation and cell apoptosis.</P>]]></description> </item><item><title><![CDATA[A Deeply Quiescent Subset of CML LSC depend on FAO yet Avoid Deleterious
ROS by Suppressing Mitochondrial Complex I]]></title><link>https://www.benthamscience.comarticle/134302</link><description><![CDATA[<P>Background and Objective: Disease relapse and therapy resistance remain serious impediments to treating cancer. Leukemia stem cells (LSC) are therapy resistant and the cause of relapse. A state of deep quiescence appears to enable cancer stem cells (CSC) to acquire new somatic mutations essential for disease progression and therapy resistance. Both normal hematopoietic stem cells (HSC) and LSC share many common features, thereby complicating the safe elimination of LSC. A recent study demonstrated that long lived normal oocytes exist without mitochondrial complex I (MC-1), expressing it in a developmentally regulated fashion, thereby mitigating their vulnerability to ROS. Quiescent CSC rely on mitochondrial FAO, without complex I expression, thereby avoiding the generation of damaging ROS, similar to long lived normal human stem cells. A deeper understanding of the biology of therapy resistance is important for the development of optimal strategies to attain complete leukemia cures. <P> Methods: Here, using scRNA-sequencing and ATAC-seq on primary chronic myelogenous leukemia (CML) patient samples, combined with bioinformatics analyses, we further examine the heterogeneity of a previously characterized in vitro imatinib-selected CD34-CD38- CML LSC population. We utilized a series of functional analyses, including single-cell metabolomic and Seahorse analyses, to validate the existence of the deepest quiescent leukemia initiators (LI) subset. <P> Results: Current study revealed heterogeneity of therapy resistant LSC in CML patients and their existence of two functionally distinct states. The most deeply quiescent LI suppress the expression of MC-1, yet are highly dependent on fatty acid oxidation (FAO) for their metabolic requirements and ATAC-seq demonstrated increased chromatin accessibility in this population, all consistent with an extremely primitive, quiescent stemness transcriptional signature. Importantly, the specific CREB binding protein (CBP)/&#946;-catenin antagonist ICG-001 initiates the differentiation of LSC, including LI, decreases chromatin accessibility with differentiation and increasing expression of MC-1, CD34, CD38 and BCR-ABL1, thereby resensitizing them to imatinib. <P> Conclusion: We investigated the biological aspects related to LSC heterogeneity in CML patients and demonstrated the ability of specific small molecule CBP/&#946;-catenin antagonists to safely eliminate deeply quiescent therapy resistant CSC. These observations may represent an attractive generalizable therapeutic strategy that could help develop better protocols to eradicate the quiescent LSC population.</P>]]></description> </item><item><title><![CDATA[Advancements in the Research of GEF-H1: Biological Functions and Tumor
Associations]]></title><link>https://www.benthamscience.comarticle/138153</link><description><![CDATA[Guanine nucleotide exchange factor H1 (GEF-H1) is a unique protein modulated by the GDP/GTP exchange. As a regulator of the Rho-GTPase family, GEF-H1 can be activated through a microtubule-depended mechanism and phosphorylation regulation, enabling it to perform various pivotal biological functions across multiple cellular activities. These include the regulation of Rho-GTPase, cytoskeleton formation, cellular barrier, cell cycle, mitosis, cell differentiation, and vesicle trafficking. Recent studies have revealed its crucial effect on the tumor microenvironment (TME) components, promoting tumor initiation and progress. Consequently, an in-depth exploration of GEF-H1’s biological roles and association with tumors holds promise for its potential as a valuable molecular target in tumor treatment.]]></description> </item><item><title><![CDATA[Arsenic Exposure and Amyloid Precursor Protein Processing: A Focus on
Alzheimer's Disease]]></title><link>https://www.benthamscience.comarticle/135578</link><description><![CDATA[<p>Background: Arsenic is present in above permissible safe limits in groundwater, soil, and food, in various areas of the world. This is increasing exposure to humankind and affecting health in various ways. Alternation in cognition is one among them. Epidemiological research has reflected the impact of arsenic exposure on children in the form of diminished cognition. <p> Aims: Considering this fact, the present study reviewed the impact of arsenic on amyloid precursor protein, which is known to cause one of the commonest cognitive disorders such as Alzheimer’s disease. <p> Methods: The present study reviews the arsenic role in the generation of amyloid-beta from its precursor that leads to Alzheimer’s disease through the published article from Pubmed and Scopus. <p> Description: According to the findings, regular, long-term exposure to arsenic beginning in infancy changes numerous arsenic level-regulating regions in the rat brain, which are related to cognitive impairments. Arsenic also affects the BBB clearance route by increasing RAGE expression. Arsenic triggers the proamyloidogenic pathway by increasing APP expression and subsequently, its processing by β-secretase and presenilin. Arsenic also affects mitochondrial dynamics, DNA repair pathway and epigenetic changes. The mechanism behind all these changes is explained in the present review article. <p> Conclusion: A raised level of arsenic exposure affects the amyloid precursor protein, a factor for the early precipitation of Alzheimer’s disease.</p>]]></description> </item><item><title><![CDATA[Anticancer Properties of Baicalin against Breast Cancer and other
Gynecological Cancers: Therapeutic Opportunities based on Underlying
Mechanisms]]></title><link>https://www.benthamscience.comarticle/138003</link><description><![CDATA[Gynecological cancers are serious life-threatening diseases responsible for high morbidity and mortality around the world. Chemotherapy, radiotherapy, and surgery are considered standard therapeutic modalities for these cancers. Since the mentioned treatments have undesirable side effects and are not effective enough, further attempts are required to explore potent complementary and/or alternative treatments. This study was designed to review and discuss the anticancer potentials of baicalin against gynecological cancers based on causal mechanisms and underlying pathways. Traditional medicine has been used for thousands of years in the therapy of diverse human diseases. The therapeutic effects of natural compounds like baicalin have been widely investigated in cancer therapy. Baicalin was effective against gynecological cancers by regulating key cellular mechanisms, including apoptosis, autophagy, and angiogenesis. Baicalin exerted its anticancer property by regulating most molecular signaling pathways, including PI3K/Akt/mTOR, NF&#954;B, MAPK/ERK, and Wnt/&#946;-catenin. However, more numerous experimental and clinical studies should be designed to find the efficacy of baicalin and the related mechanisms of action.]]></description> </item><item><title><![CDATA[The Mediating Role of miR-451/ETV4/MMP13 Signaling Axis on Epithelialmesenchymal
Transition in Promoting Non-small Cell Lung Cancer Progression]]></title><link>https://www.benthamscience.comarticle/133068</link><description><![CDATA[<P>Background: Lung cancer is a leading cause of cancer mortality. It is one of the most abundant cancer types clinically, with 2 million new cases diagnosed yearly. <P> Aims: Using clinically collected non-small cell lung cancer (NSCLC) samples, we sought to hypothesize an innovative intact signaling cascade for the disorder. <P> Methods: We dissected snap-frozen NSCLC tissues along with sibling-paired nearby non-tumorous tissues from 108 NSCLC patients. We measured the expression levels of miR-451/ETV4/MMP13 using qRT-PCR and did a thorough investigation of the molecular mechanism for the signaling axis in NSCLC cell line A549. We also studied the epithelial-mesenchymal transition (EMT) process. <P> Results: The activity of miR-451 was significantly decreased in NSCLC tissues, while the expression levels of ETV4 and MMP13 were remarkably increased. At the same time, miR-451 levels maintained a declining trend across TNM stage I–III. Inversely, ETV4 and MMP13 increased as the TNM stage increased. The miR-451/ETV4/MMP13 signaling axis was closely associated with prognosis in NSCLC patients. Based on in vitro experiments, ETV4 was a direct targeting factor for miRNA-451. Meanwhile, ETV4 promoted the tumor properties of NSCLC cells by directly activating MMP13. Silencing MMP13 blocked the EMT progress of NSCLC cells. <P> Conclusion: Overall, we hypothesized an impeccable signaling pathway for NSCLC from a new aspect, and this can offer alternative insights for a better understanding of the disorder.</P>]]></description> </item><item><title><![CDATA[Natural Compound Dioscin Targeting Multiple Cancer Pathways through its High Affinity Binding to B Cell Lymphoma-2]]></title><link>https://www.benthamscience.comarticle/138606</link><description><![CDATA[<p>Objectives: The study aimed to explore the crucial genes involved in cancer-related biological processes, including EMT, autophagy, apoptosis, anoikis, and metastasis. It also sought to identify common genes among the pathways linked to these biological processes, determine the level of Bcl-2 expression in various types of cancers, and find a potent inhibitor of Bcl-2 among natural compounds. </p> <p> Methods: Common genes involved in the pathways related to EMT, autophagy, apoptosis, anoikis, and metastasis were explored, and the level of the most frequently overexpressed gene that was Bcl-2, in various types of cancers was analyzed by gene expression analysis. A set of 102 natural compounds was sorted according to their docking scores using molecular docking and filtering. The top-ranked molecule was chosen for additional molecular dynamics (MD) simulation for 100 ns. Differential gene expression analysis was performed for Dioscin using GEO2R. </p> <p> Results: The study identified four common genes, Bcl-2, Bax, BIRC3, and CHUK, among the pathways linked to EMT, autophagy, apoptosis, anoikis, and metastasis. Bcl-2 was highly overexpressed in many cancers, including Acute Myeloid Leukemia, Diffuse large B cell lymphoma, and Thymoma. The Dioscin structure in the Bcl-2 binding site received the highest docking score and the most relevant interactions. Dioscin's determined binding free energy by MM/GBSA was -52.21 kcal/mol, while the same calculated by MM/PBSA was -9.18 kcal/mol. A p-value of less than 0.05 was used to determine the statistical significance of the analysis performed using GEO2R. It was observed that Dioscin downregulates Bcl-2, BIRC3, and CHUK and upregulates the pro-apoptotic protein Bax. </p> <p> Conclusion: The study concluded that Dioscin has the potential to act as a protein inhibitor, with a noteworthy value of binding free energy and relevant interactions with the Bcl-2 binding site. Dioscin might be a good alternative for targeting multiple cancer pathways through a single target.</p>]]></description> </item><item><title><![CDATA[Analysis of Anti-Cancer Effects in Grapefruit-based Drug Development:
A Narrative Review]]></title><link>https://www.benthamscience.comarticle/136555</link><description><![CDATA[Cancer remains a significant global health concern, and natural compounds found in fruits and vegetables have shown potential anti-cancer effects. Grapefruit (<i>Citrus paradisi</i>) has gained attention due to its rich phytochemical composition and biological activities, including anti-cancer properties. This narrative review analyzes the literature on grapefruit-based drug development and its potential as an adjunctive or alternative therapeutic strategy for cancer treatment. Grapefruit-derived compounds have been extensively studied for their anti-cancer effects, with preclinical studies showing promising outcomes in inhibiting cancer cell growth and proliferation. Compounds made from grapefruit also have anti-cancer effects. They do this in a number of ways, such as by affecting the cell cycle, apoptosis, angiogenesis, metastasis, and key signalling pathways. Petrified grapefruit compounds have potential synergistic effects with conventional chemotherapy drugs, enhancing cytotoxic effects while reducing adverse side effects. They have shown promising results in overcoming drug resistance, a major obstacle in cancer treatment. However, challenges such as bioavailability, drug interactions, and variability in compound composition remain. Overall, grapefruit-derived compounds possess significant anti-cancer properties and warrant further investigation for clinical application.]]></description> </item><item><title><![CDATA[Targeted Cancer Stem Cell Therapeutics: An Update]]></title><link>https://www.benthamscience.comarticle/138096</link><description><![CDATA[Cancer stem cells (CSCs) have become a key player in the growth of tumors, the spread of cancer, and the resistance to therapeutic interventions. Targeting these elusive cell populations has the potential to fundamentally alter cancer treatment plans. CSCs, also known as tumor-initiating cells (TICs), are thought to play a role in both medication resistance and cancer recurrence. This is explained by their capacity to regenerate themselves and change into different kinds of cancer cells. Due to their higher expression of ATP-binding cassette (ABC) membrane transporters, enhanced epithelial to mesenchymal (EMT) characteristics, improved immune evasion, activation of survival signaling pathways, and improved DNA repair mechanisms, CSCs exhibit extraordinary resistance to therapies. This comprehensive analysis delves into advancements in the domain of Targeted Cancer Stem Cell Therapeutics, concentrating on unraveling the distinctive traits of CSCs and the therapeutic methods devised to eliminate them.]]></description> </item><item><title><![CDATA[Large B-cell Lymphoma with IRF4 Rearrangement in the Nasolacrimal Duct: A Clinicopathological Study of One Case and Literature Review]]></title><link>https://www.benthamscience.comarticle/137906</link><description><![CDATA[<p>Background: Large B-cell lymphoma (LBCL) with interferon regulatory factor 4 (IRF4) rearrangement (LBCL-IRF4) is a rare subtype of LBCL, with a high prevalence in Waldeyer's ring as well as the neck, head and gastrointestinal lymph nodes. </p> <p> Materials and Methods: A patient with 2-month clinical symptoms of nasal obstruction and facial swelling was reported in this short review. A nasal endoscopy examination revealed a neoplasm in the inferior nasal meatus. Both CT and enhanced MRI showed that a soft tissue occupied the nasolacrimal duct, with bone destruction, and extended into the left nasal cavity and left lacrimal gland area. Then, a biopsy of the neoplasm in the inferior nasal meatus was performed. </p> <p> Results: HE staining results showed that neoplastic cells presented diffuse growth patterns, abundant cytoplasm, vacuole shape, lightly stained nuclei, and irregular nuclear membrane. Immunohistochemistry staining results revealed MUM1(+), Bcl- 6(+), CD20(+), CD79&#945;(+), and CD10(+). FISH analyses detected positive IRF4 rearrangement. LBCL-IRF4 was diagnosed in the patient. The patient received treatment with four cycles of R‐CHOP and two times of rituximab, followed up for 2 years, and finally got complete remission. </p> <p> Conclusion: For the first time, we summarize the imaging and pathological features, drug treatment, and curative effect of LBCL-IRF4 in the nasolacrimal duct.</p>]]></description> </item><item><title><![CDATA[Immunoglobulin G4 (IgG4)-related Lymphadenopathy in Submandibular Space
Mimicking Submandibular Malignant Tumor: A Case Report]]></title><link>https://www.benthamscience.comarticle/138391</link><description><![CDATA[<p>Background: Immunoglobulin G4 (Ig G4)-related disease is rare; however, it is a fibroinflammatory disease that has been studied a lot so far. Although the expression pattern varies depending on the organ affected, it usually manifests as organ hypertrophy and organ dysfunction. <p> Case Presentation: A 46-year-old man was referred to our otorhinolaryngology department for left submandibular swelling and tenderness that occurred 2 weeks ago. He was treated with antibiotics (augmentin 625mg, per oral) for 2 weeks, but his symptoms did not improve, and his white blood cell (WBC) count was 10,500 /μL (normal 3,800−10,000 /μL). <p> Conclusion: A mass-like lesion of the submandibular space has been concluded and the laboratory findings have been satisfactory (IgG4 level); IgG4-related disease, which is rare, but recently often reported, can be included in the differential diagnosis.</p>]]></description> </item><item><title><![CDATA[Sclerosing Angiomatoid Nodular Transformation of the Spleen: Radiological
Findings and Radiological-pathological Correlation]]></title><link>https://www.benthamscience.comarticle/131213</link><description><![CDATA[<p>Introduction: The objective of this study was to describe the CT and MRI features of sclerosing angiomatoid nodular transformation (SANT) of the spleen with pathologic correlation. <p> Materials and Methods: Ten patients with surgically resected and pathologically confirmed SANTs were included. Clinical history was reviewed, and gross pathologic, histologic, and immunohistochemical findings were recorded. CT and MRI examinations were evaluated by two radiologists. <p> Results: Patients included seven men and three women, with a mean age of 42.9±16.7 years. Pathologic features of SANTs involved multiple angiomatous nodules in a radiating pattern with a central stellate fibrous scar and evidence of hemosiderin deposition. 9 cases showed a lobulated demarcated margin, 8 cases a slight hypoattenuating, 1 isoattenuating, and 1 case with two lesions demonstrated a slight hyperattenuating margin, respectively. Multiple scattered punctate calcifications were involved in 2 cases. 5 cases manifested hypointensity on in-phase imaging, 1 iso-intensity, and 4 iso-hypointensity on out-of-phase imaging. Progressive and centripetal enhancement were exhibited in 10 cases, spoke-wheel pattern in 3 cases, and nodular enhancement in 4 cases, respectively. The central fibrous scar was identified in 8 cases during delayed enhancement. <p> Conclusion: Characteristics of SANTs on CT/MRI reflected the underlying pathology. Hypointensity on DWI and T2WI, and change of signal on T1 chemicalshift imaging were found to be due to hemosiderin deposition and fibrous tissue. Typical feature was a solitary, round, lobulated mass with a fibrous scar. Progressive and centripetal enhancement, spoke-wheel pattern, nodular enhancement, and delayed enhancement of central fibrous scar were observed.</p>]]></description> </item><item><title><![CDATA[Establishing Protocol-based Dose Metrics for Common Abdomen and Pelvis
Computed Tomography Protocols]]></title><link>https://www.benthamscience.comarticle/131993</link><description><![CDATA[<p>Background: The majority of the existing diagnostic reference levels (DRLs) that have been established for computed tomography (CT) are based on various anatomical locations, such as the head, chest, abdomen, etc. However, DRLs are initiated to improve radiation protection by conducting a comparison of similar examinations with similar objectives. The aim of this study was to explore the feasibility of establishing dose baselines based on common CT protocols for patients who underwent enhanced CT abdomen and pelvis exams. <p> Methods: Dose length product total (tDLPs), volumetric CT dose index (CTDI<sub>vol</sub>), size-specific dose estimate (SSDE), effective dose (E), and scan acquisition parameters for a total of 216 adult patients, who underwent an enhanced CT abdomen and pelvis exams over a one-year period, were obtained and retrospectively analyzed. Spearman coefficient and one-way ANOVA tests were used to check significant differences between dose metrics and the different CT protocols. <p> Results: The data exhibited 9 different CT protocols to acquire an enhanced CT abdomen and pelvis exam at our institute. Out of these, 4 were found more common, i.e., CT protocols were acquired for a minimum of 10 cases. Triphasic liver demonstrated the highest mean and median tDLPs across all 4 CT protocols. Triphasic liver protocol registered the highest E followed by gastric sleeve protocol with a mean of 28.7 and 24.7 mSv, respectively. Significant differences (p < 0.0001) were found between the tDLPs of anatomical location and the CT protocol. <p> Conclusion: Evidently, wide variability exists across CT dose indices and patient dose metrics relying on anatomical-based dose baseline, i.e., DRLs. Patient dose optimizations require establishing dose baselines based on CT protocols rather than the anatomical location.</p>]]></description> </item><item><title><![CDATA[A Case of Nasal Extranodal NK/T-cell Lymphoma of Lower Limb Muscle
Revealed by 18F-FDG PET/CT]]></title><link>https://www.benthamscience.comarticle/138996</link><description><![CDATA[<p>Background: Extranodal NK/T-cell lymphoma (ENKTCL) is a type of malignant non-Hodgkin’s lymphoma originating from mature T cells and NK cells, mainly involving the upper aerodigestive tract, including the nasal cavity, nasopharynx, oropharynx, oral cavity, hypopharynx, larynx, and occasionally the skin, salivary glands, testes, and gastrointestinal tract, but rarely the skeletal muscle. <p> Case Presentation: An 82-year-old man presented with redness, swelling, and pain in his right lower limb for 3 months. He was initially diagnosed with cellulitis at another hospital and was treated conservatively for two weeks without improvement. He underwent a biopsy of the lesioned muscle and histopathology revealed nasal type ENKTCL. 18F-FDG PET/CT was recommended for the staging of the lymphoma, and the results showed that except for the muscles of the right lower extremity, no other organs and tissues were involved. <p> Conclusion: ENKTCL confined to the muscle of the lower extremity is rare and often initially misdiagnosed as myositis because of red, swollen, heat, and painful symptoms that resemble inflammation, and in it, higher radiotracer uptake in 18F-FDG PET/CT helps to distinguish it from myositis.</p>]]></description> </item><item><title><![CDATA[Correlation of Diffusion weighted MR Imaging and ADC Values of Hepatic
Metastasis of Gastrointestinal Stromal and Gastroenteropancreatic
Neuroendocrine Tumors]]></title><link>https://www.benthamscience.comarticle/131996</link><description><![CDATA[<p>Background: DWI and ADC-mapping was performed to analyze hepatic metastasis of GIST, GEP-NET. <p> Objective: The objective of this study is to present hepatic metastasis of GIST and GEP-NET with Diffusion weighted MR imaging(DWI) and the Apparent diffusion coefficients (ADC) values of masses. <p> Methods: 18 GIST patients and 8 GEP-NET patients were examined retrospectively. 11 males and 6 females were present in GIST group, 7 males to 5 females were involved in GEP-NET group. 18 primary GIST and 10 hepatic metastasis of GIST, 8 original GEP-NET and 19 hepatic metastasis of GEP-NET; total 55 GIST and GEP-NET masses were analysed by ADC mapping. MR images were acquired by 1,5 T MR units (32 mT/min gradient strength- Achieva; Philips Healthcare, Best, Netherlands and 32 channel GE Signa GE-Wisconsin-USA); by using a 4-8 channel standard phased-array torso XL coil, all images were evaluated by an Abdominal MRI experienced radiologist. DWI was performed in the transverse plane by using spin-echo-planar imaging sequence. <p> Results: No statistical differences were observed between GIST and GEP-NET patients according to age and gender variations. No significant statistical differences were observed according to the diameters and ADC values of GIST and GEP-NET patients. A significant statistical difference was observed between GIST and GEP-NET groups in terms of size of liver metastasis which was significantly higher in GIST patients. All three groups (GIST_Hep. MET, GEP-NET_Liver_Met and normal) were statistically differed according to ADC values. With the ROC curve analysis: Hepatic metastasis of GIST(n=10) and normal liver (n:47) had cut-off value for ADC: 0.925 under AUC: 0.939 with regard to ADC values and regarded 89.4% Sensitivity, 100% Specificity, 100% PPV and 66.7% PPV. ROC curve of GEP NET_ Hepatic metastasis (n=19) group and normal liver (n:47) group presented cut-off value for ADC: 0.860 under AUC: 0.967 correlated to ADC values with 93.6% sensitivity, 89.5% specificity, 95.7% PPV and 85% PPV. <p> Conclusion: High cellular tumors resulted from liver metastasis of GIST and GEP-NET’s, and a positive correlation was observed between ADC values and cellularity/differentiation ratios of metastatic masses.</p>]]></description> </item><item><title><![CDATA[Dual-energy Spectral CT Imaging of Primary Anorectal Malignant Melanoma:
A Case Report]]></title><link>https://www.benthamscience.comarticle/134127</link><description><![CDATA[<p>Background: Primary anorectal malignant melanoma (ARMM) is a rare tumor. It is often misdiagnosed as hemorrhoids, polyps or colorectal cancer due to the lack of specificity of their clinical symptoms and imaging manifestations. <p> Case Presentation: In this study, we reported an 83-year-old female patient with ARMM. Computed tomography (CT) and Magnetic Resonance Imaging (MRI) showed uneven thickening of the intestinal wall about 7.0 cm from the anal margin, and no typical T1 high signal was seen on MRI. Dual-energy spectral CT showed that the effective atomic number (Zeff) of the tumor and the iodine concentration in the arterial phase (AP) and venous phase (VP) were different from other rectal malignancies reported in the previous literature. Sigmoidoscopy showed a large polypoid mass approximately 7.0 cm from the anal verge. Immunohistochemical staining showed that about 60% of Melan A and HMB-45 were positive, S-100 protein and Ki-67 were positive, and the pathological diagnosis was ARMM. <p> Conclusion: This was the first dual-energy spectral CT imaging report of ARMM. The Zeff and iodine concentration in the arterial phase and venous phase could help distinguish between ARMM and other rectal malignancies.</p>]]></description> </item><item><title><![CDATA[Concurrent Diffuse Dural and Leptomeningeal Enhancements in Brain
Magnetic Resonance Imaging Following a Mild COVID-19 Infection: A Novel
Case Report and Review of Literature]]></title><link>https://www.benthamscience.comarticle/130393</link><description><![CDATA[<p>Introduction: During the COVID-19 pandemic, various complications have been reported in patients with this infection worldwide, including a wide range of neurological disorders. In this study, we have reported a novel neurological complication in a 46-years-old woman who was referred due to a headache following a mild COVID-19 infection. Also, we have had a quick review of previous reports of dural and leptomeningeal involvements in COVID-19 patients. <p> Case Report: The patient's headache was persistent, global, and compressive with radiation to the eyes. The severity of the headache was increased during the disease course and was exacerbated by walking, coughing, and sneezing but decreased with rest. The high severity of the headache disrupted the patient’s sleep. Neurological examinations were completely normal, and laboratory tests did not have abnormal findings except for an inflammatory pattern. Finally, in the brain MRI, a concurrent diffuse dural enhancement and leptomeningeal involvement were observed, which is a new finding in COVID-19 patients and has not been reported so far. The patient was hospitalized and treated with Methylprednisolone pulses. After completing the therapeutic course, she was discharged from the hospital in good condition and with an improved headache. A repeated brain MRI was requested 2 months after discharge, which was completely normal and showed no evidence of dural and leptomeningeal involvements. <p> Conclusion: Inflammatory complications of the central nervous system caused by COVID-19 can occur in different forms and types, and clinicians should consider them.]]></description> </item><item><title><![CDATA[Image Quality Improvement of Low-dose Abdominal CT using Deep Learning
Image Reconstruction Compared with the Second Generation Iterative
Reconstruction]]></title><link>https://www.benthamscience.comarticle/132054</link><description><![CDATA[<p>Background: Whether deep learning-based CT reconstruction could improve lesion conspicuity on abdominal CT when the radiation dose is reduced is controversial. <p> Objectives: To determine whether DLIR can provide better image quality and reduce radiation dose in contrast-enhanced abdominal CT compared with the second generation of adaptive statistical iterative reconstruction (ASiR-V). <p> Aims: This study aims to determine whether deep-learning image reconstruction (DLIR) can improve image quality. <p> Methods: In this retrospective study, a total of 102 patients were included, who underwent abdominal CT using a DLIR-equipped 256-row scanner and routine CT of the same protocol on the same vendor&#039;s 64-row scanner within four months. The CT data from the 256-row scanner were reconstructed into ASiR-V with three blending levels (AV30, AV60, and AV100), and DLIR images with three strength levels (DLIR-L, DLIR-M, and DLIR-H). The routine CT data were reconstructed into AV30, AV60, and AV100. The contrast-to-noise ratio (CNR) of the liver, overall image quality, subjective noise, lesion conspicuity, and plasticity in the portal venous phase (PVP) of ASiR-V from both scanners and DLIR were compared. <p> Results: The mean effective radiation dose of PVP of the 256-row scanner was significantly lower than that of the routine CT (6.3±2.0 mSv vs. 2.4±0.6 mSv; p< 0.001). The mean CNR, image quality, subjective noise, and lesion conspicuity of ASiR-V images of the 256-row scanner were significantly lower than those of ASiR-V images at the same blending factor of routine CT, but significantly improved with DLIR algorithms. DLIR-H showed higher CNR, better image quality, and subjective noise than AV30 from routine CT, whereas plasticity was significantly better for AV30. <p> Conclusion: DLIR can be used for improving image quality and reducing radiation dose in abdominal CT, compared with ASIR-V.</p>]]></description> </item><item><title><![CDATA[Machine Learning in Magnetic Resonance Images of Glioblastoma: A Review]]></title><link>https://www.benthamscience.comarticle/137539</link><description><![CDATA[<p>Background: The purpose of this work was to identify which Glioblastoma (GBM) problems can be handled by Magnetic Resonance Imaging (MRI) and Machine Learning (ML) techniques. Results, limitations, and trends through a review of the scientific literature in the last 5 years were performed. Google Scholar, PubMed, Elsevier databases, and forward and backward citations were used for searching articles applying ML techniques in GBM. The 50 most relevant papers fulfilling the selection criteria were deeply analyzed. The PRISMA statement was followed to structure our report. <p> Methods: A partial taxonomy of the GBM problems tackled with ML methods was formulated with 15 subcategories grouped into four categories: extraction of characteristics from tumoral regions, differentiation, characterization, and problems based on genetics. <p> Results: The dominant techniques in solving these problems are: Radiomics for feature extraction, Least Absolute Shrinkage and Selection Operator for feature selection, Support Vector Machines and Random Forest for classification, and Convolutional Neural Networks for characterization. A noticeable trend is that the application of Deep Learning on GBM problems is growing exponentially. The main limitations of ML methods are their interpretability and generalization. <p> Conclusion: The diagnosis, treatment, and characterization of GBM have advanced with the aid of ML methods and MRI data, and this improvement is expected to continue. ML methods are effective in solving GBM-related problems with different precisions, Overall Survival being the hardest problem to solve with accuracies ranging from 57%-71%, and GBM differentiation the one with the highest accuracy ranging from 80%-97%.</p>]]></description> </item><item><title><![CDATA[Imaging Findings of Calcifying Nested Stromal-Epithelial Tumour of the Liver:
A Case Report and Literature Review]]></title><link>https://www.benthamscience.comarticle/139856</link><description><![CDATA[<p>Background: A calcifying nested stromal-epithelial tumour (CNSET) is an erratic primary liver malignant tumour frequently discovered in young girls and females. Neither its pathogenesis nor its nosogenesis is clearly known. While principally indolent, infrequent tumours with aggressive clinical progression have been defined. This paper describes a CNSET case with rare clinical and imaging features. <p> Case Presentation: A 17-year-old girl initially presented with enlarged lymph nodes near the main portal vein of the liver and a large liver tumour. Lesions were identified on the imaging findings obtained <i>via</i> positron emission tomography–computed tomography (CT) scanning, including an abnormal increase of heterogeneous glucose metabolism in the intrahepatic mass, with a maximum standardised uptake value of around 3.2. The CT imaging showed multiple dense shadows in the lesion, while the magnetic resonance imaging indicated a long T1 and a slightly longer T2. <p> Conclusions: This study summarises the imaging features of CNSETs to provide a reference for diagnosing liver tumours. In addition, the literature on the topics covered was systematically reviewed.</p>]]></description> </item><item><title><![CDATA[Radiomics in the Diagnosis of Gastric Cancer: Current Status and Future
Perspectives]]></title><link>https://www.benthamscience.comarticle/135372</link><description><![CDATA[Gastric cancer is a malignant cancerous lesion with high morbidity and mortality. Preoperative diagnosis of gastric cancer is challenging owing to the presentation of atypical symptoms and the diversity of occurrence of focal gastric lesions. Therefore, an endoscopic biopsy is used to diagnose gastric cancer in combination with imaging examination for a comprehensive evaluation of the local tumor range (T), lymph node status (N), and distant metastasis (M). The resolution of imaging examinations has significantly improved with the technological advancement in this sector. However, imaging examinations can barely provide valuable information. In clinical practice, an examination method that can provide information on the biological behavior of the tumor is critical to strategizing the treatment plan. Artificial intelligence (AI) allows for such an inspection procedure by reflecting the histological features of lesions using quantitative information extracted from images. Currently, AI is widely employed across various medical fields, especially in the processing of medical images. The basic application process of radiomics has been described in this study, and its role in clinical studies of gastric cancer has been discussed.]]></description> </item><item><title><![CDATA[Ultrasonographic Evaluation of Normal Liver, Spleen, and Kidney Dimensions
in a Healthy Turkish Community of Over 18 Years Old]]></title><link>https://www.benthamscience.comarticle/131992</link><description><![CDATA[<P>Background/Aims: The dimensions of the liver, spleen, and kidneys either change in primary diseases related to these organs or in secondary diseases that indirectly affect them, such as diseases of the cardiovascular system. Therefore, we aimed to investigate the normal dimensions of the liver, kidneys, and spleen and their correlations with body mass index in healthy Turkish adults. <P> Materials and Methods: A total of 1,918 adults older than 18 years of age underwent ultrasonographic (USG) examinations. Participants’ age, sex, height, weight, BMI, liver, spleen, and kidney dimensions, biochemistry and haemogram results were recorded. The relationships between organ measurements and these parameters were examined. <P> Results: A total of 1,918 patients participated in the study. Of these, 987 (51.5%) were female and 931 (48.5%) were male. The mean age of the patients was 40.74± 15.95 years. The liver length (LL) for men was found to be greater than that for women. The effect of the sex factor on the LL value was statistically significant (p = 0.000). The difference between men and women in terms of liver depth (LD) was statistically significant (p=0.004). The difference between BMI groups in terms of splenic length (SL) was not statistically significant (p=0.583). The difference between BMI groups in terms of splenic thickness (ST) was statistically significant (p=0.016). <P> Conclusion: We obtained the mean normal standard values of the liver, spleen, and kidneys in a healthy Turkish adult population. Consequently, values exceeding those in our findings will guide clinicians in the diagnosis of organomegaly and will contribute to filling the gap in this regard.</P>]]></description> </item><item><title><![CDATA[Radiological Features of Rare Non-odontogenic Lesions of the Jaws]]></title><link>https://www.benthamscience.comarticle/134204</link><description><![CDATA[<P>Background: The jaws can be affected by several lesions that manifest in the oral cavity, but little is known about non-odontogenic benign and malignant lesions and their radiological findings. <P> Introduction: Our aim was to discuss the imaging findings of non-odontogenic jaw lesions to help the surgeon in the diagnosis and formulating a differential diagnosis for this vast spectrum of jaw lesions with overlapping clinical and imaging appearances. <P> Methods: CT and MR images of the mandible, maxillofacial region, and neck were retrieved from the archive of the Radiology Department of Pamukkale University for the duration between 2012-2023 and assessed. <P> Results: A total of 8125 CT and MR images were retrospectively analyzed. The mean age of the patients was 39.5 years in females and 43.2 in males, with a range varying from 15 to 72 years. Histopathologically approved benign and malignant non-odontogenic lesions were detected in only 19 patients out of 8125 images (0.23%). Osteomyelitis and abscess were the most common (n=3; 0.03%), followed by two cases (n=2; 0.02%) of each fibrous dysplasia, hemangioma, osteosarcoma, squamous cell carcinoma, and multiple myeloma, and one case (n=1; 0.01%) of each ossifying fibroma, osteoma, lymphoma, metastasis, and solitary bone cyst. <P> Conclusion: Although non-odontogenic benign and malignant lesions of the jaw are rare, awareness of the radiological features of these lesions plays an important role in their diagnosis and management.</P>]]></description> </item><item><title><![CDATA[Renal Lesions with Low-level Enhancement on Contrast-enhanced CT Promotes
Early Detection of Drug-induced Kidney Injury in Patients Administered Anticancer
Drugs]]></title><link>https://www.benthamscience.comarticle/139905</link><description><![CDATA[<p>Background: Some patients with cancer-administered anti-cancer drugs may develop renal lesions with low-level enhancement on follow-up abdominal computed tomography (CT). <p> Objective: To explore the clinical significance of renal lesions with low-level enhancement on CT after exposure to anti-cancer drugs. <p> Methods: Medical records of patients with cancer who developed renal lesions on CT after exposure to anti-cancer drugs were retrospectively reviewed. Renal lesions were scored according to the extent of involvement, CT attenuation values of lesions and normal parenchyma were measured on precontrast CT and three phases of contrast-enhanced CT, and changes in serum creatinine (SCr) from one week before exposure to drugs to one week before and after the appearance of renal lesions were recorded. <p> Results: This study included 54 patients (86 lesions). Lesions were slightly lower density on pre-contrast CT, and less enhancing than normal renal parenchyma, especially in the delayed phase. Lesions were wedge-shaped, and involved the renal pyramid and associated renal cortex, as well as, were single or multiple, and occurred in the unilateral or bilateral kidneys. There were patchy and cord-like shadows of increased density in adjacent perirenal adipose tissue. During follow-up, lesions disappeared in 15 patients and persisted in 39 patients without significant progression. There were significant differences in renal lesions and normal renal parenchyma CT attenuation values in each phase of contrast-enhanced CT. Change in SCr level was significantly positively correlated with lesion score. <p> Conclusion: Renal lesions with low-level enhancement on CT suggest early drug-induced kidney injury. These findings will inform clinical decision-making.</p>]]></description> </item><item><title><![CDATA[Contrast-enhanced Chest Ultrasound in the Control of Transthoracic Tru-cut
Needle Biopsies: A Case Report]]></title><link>https://www.benthamscience.comarticle/133307</link><description><![CDATA[<p>Introduction: The current article presents a clinical case of ultrasound controlled transthoracic tru-cut needle biopsy of a small metastatic lesion in the left lung, performed with contrast-enhanced ultrasonography (CEUS). The following case demonstrates a real-time interventional manipulation of a very small lesion, which was done under local anesthesia, with a minimal invasion to the patient. <p> Case Presentation: A 72-year-old woman is presented, hospitalized for a left-sided pleural effusion with bilateral, multiple nodulеs of different sizes in the lungs. Thoracentesis revealed data for atypical cells in the pleural fluid. The CT scan suspected a probable neoplastic process, but the subsequently performed fiberbronchoscopy couldn’t prove the existence of the same. The final diagnosis was established after ultrasound controlled transthoracic tru-cut needle biopsy of a pulmonary lesion with the application of a contrast medium. <p> Conclusion: The CEUS allows precise detection of the metastatic area because of its unique perfusion characteristics and ability to remain hypocontrasted after the application of the contrast medium sulfur hexafluoride. The persistence of a concomitant left-sided pleural effusion is used as an ultrasound window during the performance of the manipulation, with the successful verification of the pathology as primary pulmonary adenocarcinoma. By the application of this minimally invasive manipulation, an accurate final histological result was obtained.</p>]]></description> </item><item><title><![CDATA[Performance of the Iterative OSEM and HYPER Algorithm for Total-body PET
at SUVmax with a Low 18F-FDG Activity, a Short Acquisition Time and Small
Lesions]]></title><link>https://www.benthamscience.comarticle/139356</link><description><![CDATA[<p>Objective: The primary objective of this comparative investigation was to examine the qualitative attributes of image reconstructions utilizing two distinct algorithms, namely OSEM and HYPER Iterative, in total-body 18F- FDG PET/CT under various acquisition durations and injection activities. <p> Methods: An initial assessment was executed using a NEMA phantom to compare image quality engendered by OSEM and HYPER Iterative algorithms. Parameters such as BV, COV, and CRC were meticulously evaluated. Subsequently, a prospective cohort study was conducted on 50 patients, employing both reconstruction algorithms. The study was compartmentalized into distinct acquisition time and dosage groups. Lesions were further categorized into three size-based groups. Quantifiable metrics including SD of noise, SUV<sub>max</sub>, SNR, and TBR were computed. Additionally, the differences in values, namely &#916;SUV<sub>max</sub>, &#916;TBR, %&#916;SUV<sub>max</sub>, %&#916;SD, and %&#916;SNR, between OSEM and HYPER Iterative algorithms were also calculated. <p> Results: The HYPER Iterative algorithm showed reduced BV and COV compared to OSEM in the phantom study, with constant acquisition time. In the clinical study, lesion SUV<sub>max</sub>, TBR, and SNR were significantly elevated in images reconstructed using the HYPER Iterative algorithm in comparison to those generated by OSEM (p &#60; 0.001). Furthermore, an amplified increase in SUV<sub>max</sub> was predominantly discernible in lesions with dimensions less than 10 mm. Metrics such as %&#916;SNR and %&#916;SD in HYPER Iterative exhibited improvements correlating with reduced acquisition times and dosages, wherein a more pronounced degree of enhancement was observable in both &#916;SUV<sub>max</sub> and &#916;TBR. <p> Conclusion: The HYPER Iterative algorithm significantly improves SUV<sub>max</sub> and reduces noise level, with particular efficacy in lesions measuring ≤ 10 mm and under conditions of abbreviated acquisition times and lower dosages.</p>]]></description> </item><item><title><![CDATA[Application of Machine-learning based on Radiomics Features in Differential
Diagnosis of Superficial Lymphadenopathy]]></title><link>https://www.benthamscience.comarticle/137212</link><description><![CDATA[<P>Objective: The accurate diagnosis of superficial lymphadenopathy is challenging. We aim to explore a non-invasive and accurate machine-learning method for distinguishing benign lymph nodes, lymphoma, and metastatic lymph nodes. <P> Methods: The clinical data and ultrasound images of 160 patients with superficial lymphadenopathy (58 benign lymph nodes, 62 lymphoma, 40 metastatic lymph nodes) admitted to our hospital from January 2020 to November 2022 were retrospectively studied. Patients were randomly divided into a training set and test set according to the ratio of 6:4. Firstly, the radiomics features of each lymph node were extracted, and then a series of statistical methods were used to avoid over-fitting. Then, the gradient boosting machine(GBM) was used to build the model. The area under receiver(AUC) operating characteristic curve, precision, recall rate and F1 value were calculated to evaluate the effectiveness of the model. <P> Results: Ten robust features were selected to build the model. The AUC values of benign lymph nodes, lymphoma and metastatic lymph nodes in the training set were 1.00, 0.98 and 0.99, and the AUC values of the test set were 0.96, 0.84 and 0.90, respectively. <P> Conclusion: It was a reliable and non-invasive method for the differential diagnosis of lymphadenopathy based on the model constructed by machine learning.</P>]]></description> </item><item><title><![CDATA[Immunoglobulin G4-related Disease with Multiple Organs Involvement
Depicted on FDG PET/CT: A Case Report and Literature Review]]></title><link>https://www.benthamscience.comarticle/134461</link><description><![CDATA[<P>Introduction: Immunoglobulin G4-related disease (IgG4-RD) is a relatively rare immune-mediated chronic inflammatory disease with fibrosis newly defined in recent years. It can involve multiple systems and organs with complex clinical manifestations. Due to mass-like lesions, it is easily misdiagnosed as tumors. <P> Case Report: Herein, we report a 57-year-old woman treated for submandibular mass and anosmia. The serum IgG4 level was increased. The biopsy of the submandibular gland indicated salivary gland tissue and hyperplasia of fibrous tissue and lymphoid tissue. Immunohistochemical examination showed a large number of IgG4-positive plasma cells. M protein was found in the patient's serum by immunofixation electrophoresis, and plasma cell diseases were excluded by bone marrow puncture. PET/CT examination showed that besides the submandibular glands, the parotid gland, common bile duct, the transitional part of the left renal pelvis and ureter, retroperitoneum in the lower abdomen, and multiple lymph nodes were also involved. The patient was diagnosed with IgG4-RD, and after treatment with glucocorticoid, the enlargement of submandibular glands and decreased olfactory function improved. After 14 weeks of treatment, the serological examinations, PET/CT, and ultrasound re-examination results showed significant improvement. So far, the patient has been followed up for 27 months and is in continuous remission. <P> Conclusion: This case report aims to raise awareness of IgG4-RD and explore the value of PET/CT in the diagnosis and efficacy monitoring of the disease.</P>]]></description> </item><item><title><![CDATA[Disease Quantification of Liver Lymphoma in CT Images without Lesion
Segmentation]]></title><link>https://www.benthamscience.comarticle/132186</link><description><![CDATA[<p>Aim: This study aimed to automatically implement liver disease quantification (DQ) in lymphoma using CT images without lesion segmentation. <p> Background: Computed Tomography (CT) imaging manifestations of liver lymphoma include diffuse infiltration, blurred boundaries, vascular drift signs, and multiple lesions, making liver lymphoma segmentation extremely challenging. <p> Methods: The method includes two steps: liver recognition and liver disease quantification. We use the transfer learning technique to recognize the diseased livers automatically and delineate the livers manually using the CAVASS software. When the liver is recognized, liver disease quantification is performed using the disease map model. We test our method in 10 patients with liver lymphoma. A random grouping cross-validation strategy is used to evaluate the quantification accuracy of the manual and automatic methods, with reference to the ground truth. <p> Results: We split the 10 subjects into two groups based on lesion size. The average accuracy for the total lesion burden (TLB) quantification is 91.76% ± 0.093 for the group with large lesions and 95.57% ± 0.032 for the group with small lesions using the manual organ (MO) method. An accuracy of 85.44% ± 0.146 for the group with larger lesions and 81.94% ± 0.206 for the small lesion group is obtained using the automatic organ (AO) method, with reference to the ground truth. <p> Conclusion: Our DQ-MO and DQ-AO methods show good performance for varied lymphoma morphologies, from homogeneous to heterogeneous, and from single to multiple lesions in one subject. Our method can also be extended to CT images of other organs in the abdomen for disease quantification, such as Kidney, Spleen and Gallbladder.</p>]]></description> </item><item><title><![CDATA[Efficacy of Endobronchial Ultrasound-guided Transbronchial Needle Aspiration
in the Diagnosis of Mediastinal and Hilar Lesions]]></title><link>https://www.benthamscience.comarticle/131325</link><description><![CDATA[<p>Background: Mediastinal and hilar lesions may be benign or malignant. Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) is increasingly used for the diagnosis of these lesions as it is both minimally invasive and safe. <p> Objective: To investigate the clinical efficacy of EBUS-TBNA in the diagnosis and differential diagnosis of mediastinal and hilar lesions. <p> Methods: A retrospective observational study was undertaken to investigate patients diagnosed with mediastinal and hilar lymphadenopathy based on imaging at our hospital from 2020 to 2021. After evaluation, EBUS TBNA was used and data including the puncture site, postoperative pathology, and complications were recorded. <p> Results: Data from 137 patients were included in the study, of which 135 underwent successful EBUS TBNA. A total of 149 lymph node punctures were performed, of which 90 punctures identified malignant lesions. The most common malignancies were small-cell lung carcinoma, adenocarcinoma, and squamous cell carcinoma. Forty-one benign lesions were identified, resulting from sarcoidosis, tuberculosis, and reactive lymphadenitis, amongst others. Follow-up findings showed that 4 cases were malignant tumors, with 1 case of pulmonary tuberculosis and 1 case of sarcoidosis). Four specimens where lymph node puncture was insufficient were subsequently confirmed by other means. The sensitivity of EBUS TBNA for malignant lesions, tuberculosis and sarcoidosis in mediastinal and hilar lesions was 94.7%, 71.4%, and 93.3%, respectively. Similarly, the negative predictive values (NPV) were 88.9%, 98.5%, and 99.2%, and the accuracy was 96.3%, 98.5%, and 99.3%. <p> Conclusion: EBUS TBNA is an effective and feasible approach for the diagnosis of mediastinal and hilar lesions that is minimally invasive and safe.</p>]]></description> </item><item><title><![CDATA[Does Post-/Long-COVID-19 Affect Renal Stiffness without Causing any Chronic
Systemic Disorders?]]></title><link>https://www.benthamscience.comarticle/138802</link><description><![CDATA[<p>Background: In the last few years, coronavirus disease 2019 (COVID-19) has changed human lifestyle, behavior, and perception of life. This disease is caused by severe acute respiratory syndrome coronavirus 2 (SARS-COV-2). In the literature, there are limited studies about the late renal effects of COVID-19 that reflect the systemic involvement of this disease. <p> Aim: In the present study, we aimed to compare sonoelastographic changes in both kidneys between patients who had totally recovered from COVID-19 and healthy individuals using strain wave elastography (SWE). <p> Methods: This study was conducted between June 2021 and May 2022 in Kahramanmaraş City Hospital Department of Radiology. File and archive records were retrospectively evaluated. Basic demographic, laboratory, and renal ultrasonography (USG) and sonoelastographic findings were screened and noted. Two groups were defined to compare sonoelastographic findings. Post-/long-COVID-19 group had 92 post-long COVID-19 patients, and the comparator group comprised healthy individuals”. Both groups’ demographic, laboratory, and ultrasound-elastographic findings were assessed. <p> Results: The post-long COVID-19 group had a higher renal elastographic value than the comparator group (1.52 [0.77–2.3] vs. 0.96 [0.54–1.54], p&#60;0.001). There were no statistically significant differences between the two groups in terms of age (p=0.063), gender (p=0.654), or body mass index (BMI) (p=0.725), however, there was a significant difference observed between the two groups in the renal strain ratio (RSR). According to an receiver operating characteristic curve (ROC) analysis, an RSR cutoff of >1.66 predicted post-long COVID-19 with 44.9% sensitivity and 81.9% specificity. (AUC=0.655, p&#60;0.001). A separate ROC analysis was performed to predict post-long COVID-19 with a BMI cutoff of &#60;33.52, kg/m2 sensitivity of 92.4% and specificity of 17% (AUC=0.655, p&#60;0.001). <p> Conclusion: We demonstrated that renal parenchymal stiffness increases with SWE in post-long COVID-19 patients.]]></description> </item><item><title><![CDATA[Infiltrating Metastatic Ductal Carcinoma Initially Presenting as Axillary Lymph
Node Metastases Diagnosed with PET/CT and MRI: Case Report and Brief
Review of Occult Breast Carcinoma]]></title><link>https://www.benthamscience.comarticle/131770</link><description><![CDATA[<p>Introduction: The concept of occult breast carcinoma (OBC) was first described in 1907 by Halsted, who described this type of breast cancer to arise from small, undetectable tumours in the breast that had already metastasized to the lymph nodes. Although the breast is the most likely site for the primary tumour, non-palpable breast cancer presenting as an axillary metastasis has been reported, but with a low frequency of less than 0.5% of all breast cancers. OBC represents a complex diagnostic and therapeutic dilemma. Considering its rarity, clinicopathological information is still limited. <p> Case Report: A 44-year-old patient presented to the emergency room with an extensive axillary mass as the first manifestation. Conventional evaluation of the breast with mammography and ultrasound was unremarkable. However, a breast MRI confirmed the presence of conglomerate axillary nodes. A supplementary whole-body PET-CT established the axillary conglomerate with a malignant behaviour with SUVmax of 19.3. The primary tumour was not detected in the breast tissue of the patient, confirming the diagnosis of OBC. Immunohistochemical results showed positive receptors for estrogen and progesterone. <p> Conclusion: Although OBC is a rare diagnosis, its existence is a possibility in a patient with breast cancer. Mammography and breast ultrasound with unremarkable findings but with high clinical suspicion should be supplemented with additional imaging methods, such as MRI and PET-CT, emphasizing the appropriate pre-treatment evaluation.</p>]]></description> </item><item><title><![CDATA[A Comprehensive Review of <i>Abroma Augusta</i> (Devil's Cotton): Phytochemical
Constituents, Ethnomedicinal Applications, and Pharmacological Properties]]></title><link>https://www.benthamscience.comarticle/136596</link><description><![CDATA[The nutritional and therapeutic potential of medicinal plants is constantly being investigated. This is especially relevant in today's world, where an increasing number of people are turning to complementary and alternative therapies to address their health-related concerns. Traditional knowledge, as a valuable resource, plays a crucial role in the development of new herbal medicines. <i>Abroma augusta</i> stands out as one such medicinal plant that has a rich history of use in traditional medicine. It has been employed to address a wide spectrum of health issues, including diabetes, menstrual irregularities, respiratory problems, musculoskeletal disorders, urinary ailments, and sexual dysfunctions, among others. While various parts of this plant species are believed to possess pharmacological properties, the active compounds and underlying mechanisms remain largely unexplored. To facilitate the development of innovative drugs for the benefit of individuals, this study places significant emphasis on delving into the phytochemical and ethnomedicinal attributes of <i>A. augusta</i>. Moreover, it seeks to bolster its findings with scientifically validated pharmacological investigations conducted through both <i>in vivo</i> and <i>in vitro</i> methodologies.]]></description> </item><item><title><![CDATA[Kikuchi-fujimoto Disease in the Axilla after COVID-19 Vaccination: A Case
Report]]></title><link>https://www.benthamscience.comarticle/132587</link><description><![CDATA[<P>Background: Kikuchi-Fujimoto disease (KFD) is a rare, self-limiting inflammatory condition of unknown etiology that is characterized by fever and painful lymphadenopathy. KFD commonly involves the posterior cervical region and very rarely occurs in the axilla. <P> Case Presentation: We report on a case of KFD that presented 3 weeks after receiving the messenger ribonucleic acid-based coronavirus disease 2019 (COVID-19) vaccine. In this case, we suspected the lesions as COVID-19 vaccination-related lymphadenopathy on the initial ultrasonographic examination. <P> Conclusion: Through this case report, we highlight that KFD should be considered in the differential diagnosis of patients with axillary lymphadenopathy who have undergone COVID-19 vaccination, as unusual side effects of COVID-19 vaccination have been increasingly reported in the literature owing to the rapid development of various COVID-19 vaccines during the pandemic period. In addition, we emphasize the importance of clinical suspicion in diagnosing KFD due to the fact that axillary involvement of KFD is extremely rare.</P>]]></description> </item><item><title><![CDATA[Enhanced CT Findings in a Case of Recurrent Pelvic Follicular Dendritic Cell
Sarcoma]]></title><link>https://www.benthamscience.comarticle/138154</link><description><![CDATA[<P>Introduction: Follicular Dendritic Cell Sarcomas (FDCS)was first found in 1986; the specificity of the disease is its rarity, with an incidence of only 0.4%, numerous doctors for its lack of understanding, the accuracy of imaging diagnosis is not great, which is easy to delay the treatment. This article summarizes several characteristic imaging manifestations of FDCS to provide imaging physicians with an understanding of the imaging properties of this rare disease. When faced with complex cases, the radiologist can consider this disease and include it in the differential diagnosis. FDCS occurs mainly in lymph nodes, mainly in the head and neck. The main symptoms are fatigue, local pain, or painless mass. The treatment method is not uniform, but scholars agree that we should strive for the opportunity of surgery as much as possible. <P> Case Presentation: This paper reported a case of FDCS with pelvic recurrence 3 years after surgery. The patient was suspected to have lymphoma by postoperative pathology in the local hospital, and it is recommended that the patient be reexamined regularly. A soft tissue mass was recently found again in the left pelvic cavity. After an enhanced CT examination, the radiologist was skeptical of the previous diagnosis of lymphoma. Subsequently, a needle biopsy was performed at Peking University Shougang Hospital. The pathological results rejected the prior diagnosis of lymphoma after consultation with additional hospitals, and the patient was diagnosed with FDCS. <P> Conclusions: The imaging manifestations of FDCS lack absolute specificity, but it also has imaging characteristics, such as large areas of necrosis in the huge mass, rough mass calcification in the mass, enhanced scan showed “fast in and slow out” mode, and there were blood vessels in the tumor. FDCS mainly occurs in lymph nodes and is easily misdiagnosed as GIST, inflammatory myoblastoma, lymphoma, etc. Radiologists should continue to collect cases of this disease and include suspected cases in the differential diagnosis in clinical work.</P>]]></description> </item><item><title><![CDATA[A Rare Case of Castleman's Syndrome Presentıng wıth a Mass ın the
Bıfurcatıon of the Celıac Trunk]]></title><link>https://www.benthamscience.comarticle/135456</link><description><![CDATA[<p>Introduction: Castleman's disease is an extremely rare disease in the abdomen region characterized by benign lymphoepithelial proliferation. <p> Case Presentation: We report a case of a 63-year-old female who presented with abdominal pain. Abdominal CT Angio and dynamic contrast-enhanced abdominal MRI revealed a mass lesion showing markedly contrast enhancement, no vascular invasion sign, and diffusion restriction lesion in the truncus coelicus bifurcation region. The mass was surgically resected completely. Pathological evaluation showed a hyaline-vascular type of Castleman’s disease. <p> Conclusion: Castleman's disease should be kept in mind in the differential diagnosis of an isolated intra-abdominal mass.</p>]]></description> </item><item><title><![CDATA[Rare Metastatic Embryonal Carcinoma Resembling Lymphoma: A Case Report]]></title><link>https://www.benthamscience.comarticle/139012</link><description><![CDATA[<p>Background: Embryonal carcinoma is a rare tissue type in germ cell tumors. According to our literature review, metastatic embryonal carcinoma misdiagnosed as lymphoma because of its high similarity to lymphoma is extremely rare and has not been reported yet. <p> Case Presentation: A 46-year-old middle adulthood male presented with unexplained fever, night sweats, abdominal distension for 3 months, and weight loss of around 7kg during almost 6 months, which is extremely similar to lymphoma from the clinical features and imaging examinations. After a clear diagnosis, the case not only obtained the opportunity of surgery but was also exempted from radiotherapy. The treatment effect was good. We report a case of rare metastatic embryonal carcinoma, which can provide insight into the diagnosis and treatment of embryonal carcinoma. <p> Conclusion: Metastatic embryonal carcinoma of abdominal lymph nodes can be highly similar to lymphoma; the diagnosis can only be based on clinical manifestations and imaging examination but also combined with patient history, tumor markers and biochemical examination. However, the final diagnosis depends on pathological biopsy.</p>]]></description> </item><item><title><![CDATA[Comparison of Doppler Imaging and Microvascular Imaging in Cervical Lymph
Node Blood Flow Analysis]]></title><link>https://www.benthamscience.comarticle/140477</link><description><![CDATA[Cervical lymph node metastasis is an important determinant of cancer stage and the selection of an appropriate treatment plan for patients with head and neck cancer. Therefore, metastatic cervical lymph nodes should be effectively differentiated from lymphoma, tuberculous lymphadenitis, and other benign lymphadenopathies. The aim of this work is to describe the performance of Doppler ultrasound and superb microvascular imaging (SMI) in evaluating blood flow information of cervical lymph nodes. In addition, the features of flow imaging in metastatic lymph nodes, lymphoma, and tuberculous lymphadenitis were described. Compared with Doppler ultrasound, SMI, the latest blood flow imaging technology, could detect more blood flow signals because the sensitivity, specificity, and accuracy of SMI in the diagnosis of cervical lymph node disease were higher. This article summarizes the value of Doppler ultrasound and SMI in evaluating cervical lymph node diseases and focuses on the diagnostic performance of SMI.]]></description> </item><item><title><![CDATA[The Evolution of Medical Imaging in the Therapeutics of Patients with Skin
Cancer]]></title><link>https://www.benthamscience.comarticle/137175</link><description><![CDATA[<p>Introduction: Medical imaging mechanization has reformed medical management, empowering doctors to recognize cancer prematurely and promote patient outcomes. Imaging tests are of significant influence in the detection and supervision of cancer patients. Cancer recognition generally necessitates imaging studies that, in most instances, utilize a trivial amount of radiation. Methodologies such as X-rays, computed tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography (PET) are predominant in clinical managerial, incorporating remedy and research. <p> Background: Over recent years, diagnostic imaging has progressed from a state of commencement to an advanced level. Numerous modern imaging procedures have evolved. Although contemporary medical imaging comprises image exhibition together with image refining, computer-aided diagnosis (CAD), image inscribing and conserving, and image transference, the majority of which are embraced in picture documentation and communication processes. <p> Aim: This review targets to encapsulate toxicology information on skin cancer unpredictability essential to interpretation measures, report important factor that helps in defining skin cancer condition, and possible medical care alternatives or medical attention endorsed referring to diverse aspects involving the size and site of malignancy, the complications, patient’s priority and well being. We concisely review various therapy alternatives, methods of radiation autoimmunity, prime observational study designs of medical and distinct radiation resources and cancer risks, and current analysis methodologies and research precision. <p> Conclusion: The detail of this paper covers a brief review of research and evolution in medical imaging discipline and mechanism. This review considers the physiology of melanocytes and the pathogenesis of skin cancer using medical imaging. Also, a description of risk factors, prevention methods, screening, various diagnosis methods and different stages of skin cancer, sub-types and different types of treatment methods is provided in this paper for research and development.</p>]]></description> </item><item><title><![CDATA[The Value of Nerve Ultrasound to Diagnose and Follow Up the Multifocal
Neurolyphomatosis in the Upper Limb---- Case Report and Literature Review]]></title><link>https://www.benthamscience.comarticle/139170</link><description><![CDATA[<p>Introduction: Neurolymphomatosis (NL) is a rare disease. Ultrasound (US) plays a crucial role in diagnosing and following up the NL. <p> Case Presentation: A 59-year-old man was hospitalized with acute pain in the left upper extremity. Ultrasound revealed segmental swelling of multiple nerves around his left elbow with abundant blood flow signals. Contrast-Enhanced Ultrasound (CEUS) showed a rapid, complete and homogenous enhancement in the nerve lesions in the early arterial phase. The NL was confirmed by imaging and flow cytometry, and he accepted chemotherapy. The posttherapeutic ultrasound showed that the nerves in the left upper limb were basically normal. Unfortunately, the patient died of cerebral metastasis in 5 months. <p> Conclusion: The nerve US and CEUS can show specific manifestations and provide more diagnostic information about NL.</p>]]></description> </item><item><title><![CDATA[The Efficiency of Acoustic Radiation Force Impulse (ARFI) Elastography in the
Differentiation of Renal Cell Carcinoma and Oncocytoma]]></title><link>https://www.benthamscience.comarticle/139801</link><description><![CDATA[<P>Purpose: This study is to investigate the effectiveness of Acoustic Radiation Force Impulse (ARFI) elastography in differentiating radiologically similar renal cell carcinoma (RCC) and oncocytoma in solid masses of the kidney. <P> Methods: The patients with solid renal mass histopathological diagnosed after excision or tru-cat biopsy who underwent a preoperative ARFI elastography of the lesion during a 4-year period were included in this study. Preoperative shear wave velocity (SWV) values were measured in all the lesions. SWV results of RCCs and oncocytomas were compared by an independent t-test, and cut-off, sensitivity and specificity values were calculated. <P> Results: Forty-two of the 60 patients included in the study were men (70%) and, 18 were women (30%), and the mean age was 59.7 ± 14 (27-94) years. Among 46 RCCs (76.6%), 23 and 14 oncocytomas, 5 (23.4%) were located in the right kidney (p:0.34722). Mean SWV values were found to be significantly higher in RCCs (2.87± 0.74 (0.96-4.14) m/s) than oncocytomas (1.83 ± 0.78 (0.80-3.76) m/s) (p <0.001). In the ROC analysis, a cutoff value of 2.29 m/s was found to havean 80.4% sensitivity and a 78.6% specificity for the discrimination of RCCs from oncocytomas. <P> Conclusion: ARFI elastography measurements may be useful in distinguishing RCC and oncocytomas that may have similar solid radiological imaging features.</P>]]></description> </item><item><title><![CDATA[18F-Fluorodeoxyglucose PET/CT and MRI Imaging Characteristics of
Monomorphic Epitheliotropic Intestinal T-cell Lymphoma: A Case Report]]></title><link>https://www.benthamscience.comarticle/132206</link><description><![CDATA[<P>Background: Monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL) is a rare, rapidly progressive, primary intestinal T-cell lymphoma. The most common site of occurrence is on the small intestine. The prognosis of MEITL is extremely poor due to delayed diagnosis and lack of targeted therapy. <P> Case Summary: A case of MEITL involving the entire small bowel, part of the colon, rectum, mesenteric lymph nodes, and liver is herein reported. We are presenting the 18F-FDG PET/CT features of MEITL, which showed all involved lesions with increased FDG activity. The MRI and pathological characteristics of MEITL were also described. Furthermore, some malignant diseases and benign diseases should be considered in the differential diagnosis. <P> Conclusion: Based on the lesions with a high accumulation of FDG, our case shows the involved extent of MEITL, which is helpful for biopsy and treatment option decisions. We expect more could know about this disease and make an early diagnosis to improve the outcomes of MEITL.</P>]]></description> </item><item><title><![CDATA[Imaging and Histopathological Features Of Primary Thymic Neuroendocrine
Tumor]]></title><link>https://www.benthamscience.comarticle/137399</link><description><![CDATA[<P>Objectives: To investigate CT, MRI, and PET/CT features with histopathological findings of primary thymic neuroendocrine tumor. <P> Materials and Methods: All 9 cases with pathologically proven primary thymic neuroendocrine tumors were reviewed retrospectively. Among them, 7 underwent enhanced CT, 1 with MRI (enhanced) and another with PET/CT scan. Multiple characters were examined, including tumor location, contour, CT attenuation, enhancement pattern, involvement of surrounding structure and lymphadenopathy. <P> Results: Among 9 patients studied, 7 (77%) masses were located in the anterior superior mediastinum, 1 in the anterior superior-middle mediastinum, and 1 in the anterior and middle mediastinum. The maximum diameter (longitudinal) ranged from 4.2 to 23 cm (mean ± standard deviation, 9.5 cm ± 2.8). Four masses had irregular, 3 had lobulated, and 2 had smooth contours, while 8 masses had clear margins and 1 had an ill-defined margin. Six masses showed heterogeneous attenuation with necrotic/cystic component (n=5), calcification (n=2) and hemorrhage(n=1), and 3 showed homogeneous attenuation on the non-enhanced image. After contrast administration, 8 masses showed heterogeneous attenuation, and 1 showed homogeneous attenuation with tumor vessels visible in 4 masses. Among all, 8 masses showed strong enhancement, and 1 showed moderate enhancement in comparison to muscles in the anterior thoracic wall on enhanced images. Involvement of adjacent mediastinal structures was observed in 5 cases. Immunohistochemical analysis showed that the tumor cells were positive for CgA, Syn, CK, CD56 and EMA. <P> Conclusion: Primary NETs are large masses located anterior superior mediastinum, irregular in contour, showing heterogeneous attenuation with necrotic/cystic component and strong heterogeneous enhancement with tumor vessels, compressing local mediastinal structures. In addition, immunohistochemical examination is required in such a diagnosis.</P>]]></description> </item><item><title><![CDATA[MRI Insights in Breast Imaging]]></title><link>https://www.benthamscience.comarticle/138778</link><description><![CDATA[In the world, breast cancer is the most commonly diagnosed cancer among women. Currently, MRI is the most sensitive breast imaging method for detecting breast cancer, although false positive rates are still an issue. To date, the accuracy of breast MRI is widely recognized across various clinical scenarios, in particular, staging of known cancer, screening for breast cancer in high-risk women, and evaluation of response to neoadjuvant chemotherapy. Since technical development and further clinical indications have expanded over recent years, dedicated breast radiologists need to constantly update their knowledge and expertise to remain confident and maintain high levels of diagnostic performance in breast MRI. This review aims to detail current and future applications of breast MRI, from technological requirements and advances to new multiparametric and abbreviated protocols, and ultrafast imaging, as well as current and future indications.]]></description> </item><item><title><![CDATA[A Fistulized Giant Duodenal Stromal Tumor in a Young Patient: A Case Report
With Literature Review for Tomographic Diagnosis]]></title><link>https://www.benthamscience.comarticle/129788</link><description><![CDATA[<P>Background: Duodenal gastrointestinal stromal tumors (GISTs) are rare tumors of the gastrointestinal tract. It should be considered in the differential diagnosis of periampullary region pathologies. <P> Case Report: A 24-year-old male patient applied to the general surgery department with the complaint of long-standing abdominal pain, nausea and vomiting after meals, and 8-10 kg weight loss in 1 month. Three-phase dynamic abdominopelvic CT showed that the 1st and the 2nd segments of the duodenum were dilated. At this level, a peripherally intensely contrasted heterogeneous mass lesion, 91x70x46 mm in size, was observed. There was oral contrast and air values in the center of the mass. A fistulized mass connected with the duodenal wall was considered in the differential diagnosis. In the surgical exploration, a soft, vascularized mass fistulized to the 2nd segment of the duodenum was observed. Pathological diagnosis was reported as GIST. <P> Conclusion: GISTs arise from the precursors of Cajal Interstitial cells of the gastrointestinal tract. Contrast-enhanced CT is the preferred diagnostic method for staging, risk stratification, and follow-up. We presented a young case with a giant duodenal GIST and discussed differential diagnosis and some diagnostic properties.</P>]]></description> </item><item><title><![CDATA[The Diagnostic Value of Abnormal Bone Marrow Signal Changes on Magnetic
Resonance Imaging: Is Bone Marrow Biopsy Essential?]]></title><link>https://www.benthamscience.comarticle/138997</link><description><![CDATA[<p>Background: It is essential to determine whether bone marrow signal changes on magnetic resonance imaging (MRI) represent a physiological response or pathology; at present, the clinical significance of these signal changes is unclear. It is unknown whether a bone marrow biopsy is required when bone marrow signal changes are detected incidentally in individuals without suspected malignancy. <p> Objective: The primary purpose of this study was to determine whether incidentally detected bone marrow signal changes on MRI performed for various reasons (at the time of admission or during follow-up) are clinically significant. <p> Methods: We retrospectively evaluated the bone marrow biopsy clinical and laboratory findings of 42 patients with incidental bone marrow signal changes on MRI between September 2016 and January 2020. We also determined whether the patients were diagnosed with malignancy during admission or follow-up. <p> Results: Of the 42 patients, three (7%) were diagnosed with hematological malignancies during admission, while two were diagnosed with multiple myeloma and one with B-cell acute lymphoblastic leukemia. Of the 42 patients, 35 had a mean follow-up of 40.6 ± 5.3 months. One patient was diagnosed with monoclonal gammopathy of undetermined significance four months after their first admission. <p> Conclusions: In addition to MRI, detailed clinical and laboratory evaluations should be performed to inform the decision for bone marrow biopsy and exclude hematological malignancy. If there is any doubt, a bone marrow biopsy should be performed. Moreover, since bone marrow signal changes may be a preliminary finding, follow-up of these patients is essential.</p>]]></description> </item><item><title><![CDATA[Rituximab Induced Flare of Psoriatic Arthritis in a Patient with Devic's Syndrome: A Case Report]]></title><link>https://www.benthamscience.comarticle/138892</link><description><![CDATA[<p>Introduction/Background: Devic’s syndrome is a rare autoimmune disorder that occurs when the body's immune system damages and mistakenly attacks the optic nerves and spinal cord, leading to numerous neurological symptoms such as inflammation, weakness, numbness, and vision problems. Rituximab has mainly been utilized as an immunosuppressive therapy for patients with Devic’s syndrome. Although evidence has shown that rituximab is efficient and well tolerated in treating patients with Devic’s syndrome, there is the possibility of rituximab exacerbating severe psoriasis and psoriatic arthritis flare. </p> <p> Case Presentation: In this paper, we describe a case of a 58-year-old female with Devic’s syndrome, blindness, and neurological involvement who responded exceptionally well to rituximab but developed a severe flare of psoriatic arthritis. After withdrawing from the use of rituximab, her psoriatic arthritis symptoms had resolved. However, she did have another episode of blindness, and rituximab was started once again. Although her vision improved, her psoriatic arthritis symptoms had reoccurred. The patient was switched to eculizumab and ustekinumab, which controlled both her psoriatic arthritis and Devic’s syndrome. </p> <p> Conclusion: Very few reports have identified rituximab to induce a flare-up of psoriatic arthritis, raising uncertainty regarding its potential effects on psoriatic symptoms. The precise mechanism underlying the exacerbation of psoriatic arthritis by rituximab remains uncertain. This case report highlights that rituximab can worsen psoriasis and psoriatic arthritis, and that the complexities of Devic’s syndrome may require medication adjustments.</p>]]></description> </item><item><title><![CDATA[Optimal Rituximab Monotherapy in Splenic Marginal Zone Lymphoma (SMZL): A Case Report and Brief Review]]></title><link>https://www.benthamscience.comarticle/135867</link><description><![CDATA[<p>Introduction: Splenic marginal zone Lymphoma (SMZL) is a rare, chronic B lymphocyte proliferative disease. Generally, SMZL is accompanied by circulating atypical villous lymphocytes, known as SMZL with villous lymphocytes. Rituximab is a chimeric monoclonal antibody to CD20; recent but limited studies have confirmed its effectiveness in treating SMZL. Given the low incidence and selection of treatment, statistical comparisons of rituximab monotherapy with other available treatment options with the full range of data from previous clinical studies remain sparse. Here, we report a case of SMZL with villous lymphocytes treated by rituximab monotherapy, which is especially infrequently reported. </p> <p> Case Report: A 63-year-old Chinese female was presented to the hospital with complaints of splenomegaly and pain in the spleen area. Immunohistochemistry analysis was positive for IGH, IGK, and IGL clonal rearrangement. Villous lymphocytes were found in peripheral blood and bone marrow, along with further immunotyping results. The case was considered as SMZL with villous lymphocytes. Based on the SMZLSG prognosis assessment, we applied rituximab monotherapy. After eight cycles of rituximab treatment, the patient’s condition improved markedly, with blood constituent and size of the spleen returning to normal levels, achieving complete response, with no significant side effect observed. </p> <p> Discussion: The patient provides a typical SMZL with villous lymphocytes case treated with rituximab monotherapy. Currently, the main treatment options include splenectomy and rituximab. After synthesizing a series of current views, we put forward our opinion about the selection of therapy for SMZL patients in order to gain maximum benefits for patients in need of treatment. </p> <p> Conclusion: Our analysis found no statistically significant difference between rituximab monotherapy and rituximab combined with chemotherapy, while rituximab treatments resulted in better therapeutic effects than chemotherapy. Rituximab monotherapy has favorable therapeutic effects and minor adverse effects (AEs) in treating SMZL.</p>]]></description> </item><item><title><![CDATA[Exploring the Efficacy of Herbal Medications in the Treatment of Parkinsonism: A Mini Review]]></title><link>https://www.benthamscience.comarticle/137301</link><description><![CDATA[<p>Background: Over 10 million people worldwide are affected by the chronic neurodegenerative condition of Parkinson's disease. Dopaminergic neurons in the Substantia Nigra area of the brain are gradually lost as a result. Herbal medicine, which have its roots in ancient cultures, uses medicinal herbs to treat illnesses and advance general health. There is considerable interest in researching the possibilities of herbal medicine for treating neurodegenerative diseases like Parkinson's disease because they are thought to be safer than synthetic medications. </p> <p> Objective: The objective of this article is to investigate the potential of herbal medications as a treatment option for Parkinsonism, and to provide a clear understanding of the current state of research on this topic. </p> <p> Conclusion: This review focuses on herbal treatments and components that have demonstrated promise in Parkinson's disease <i>in vitro</i> and animal models. This information can be used to identify prospective traditional medicine prescription therapies. New therapeutic treatments for Parkinson's disease may result from further study of pharmaceutical components with well-established therapeutic potential.</p>]]></description> </item><item><title><![CDATA[Biogenic Synthesis and Characterization of Ethyl Ferulate Gold Nanoparticle and its Efficacy against Triple-Negative Breast Cancer Cells]]></title><link>https://www.benthamscience.comarticle/138349</link><description><![CDATA[<p>Background: Triple-Negative Breast Cancer (TNBC) presents a significant challenge due to its aggressive nature and lack of responsive hormone receptors, predominantly affecting younger premenopausal women. Ethyl ferulate (EF), a notable phytochemical, has demonstrated promising anti-cancer properties. This study aimed to enhance the efficacy of EF by synthesizing and characterizing ethyl ferulate gold nanoparticles (EF-AuNps) to passively target TNBC cells via the enhanced permeability and retention (EPR) effect. </p> <p> Methods: We synthesized EF-AuNps using a direct reduction method and characterized the NPs by employing various techniques, including UV-visible spectroscopy, DLS, XRD, EDX, TEM, and FT-IR. The anti-proliferative activity against MDA-MB-231 cells was assessed using MTT and colony formation assays, alongside evaluating cell viability with PI-FACS and live/dead assays. Furthermore, a Western blot was performed to determine the mechanism of action of EFAuNps in TNBC cells. </p> <p> Result: We successfully synthesized triangular EF-AuNps (<100nm) and observed a substantial inhibition of cell proliferation (IC<sub>50</sub> 18μg/ml). Compared to EF alone, EF-AuNps significantly enhanced cell death in TNBC cells, as confirmed by flow cytometry and viability assays. Besides, Western blot analysis verified that the expression of apoptotic-related signal proteins, such as survivin, caspase 3, and caspase 9, were modulated by EF-AuNps. </p> <p> Conclusion: EF-AuNps showed higher anti-cancer efficacy than EF in the MDA-MB-231 cell line. These findings suggest the therapeutic potential of EF-AuNps for TNBC treatment, advocating for further preclinical and clinical investigations into this promising anti-cancer formulation.</p>]]></description> </item><item><title><![CDATA[Insights into the Emerging Therapeutic Targets of Triple-negative Breast Cancer]]></title><link>https://www.benthamscience.comarticle/138654</link><description><![CDATA[Triple-negative Breast Cancer (TNBC), the most aggressive breast cancer subtype, is characterized by the non-appearance of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). Clinically, TNBC is marked by its low survival rate, poor therapeutic outcomes, high aggressiveness, and lack of targeted therapies. Over the past few decades, many clinical trials have been ongoing for targeted therapies in TNBC. Although some classes, such as Poly (ADP Ribose) Polymerase (PARP) inhibitors and immunotherapies, have shown positive therapeutic outcomes, however, clinical effects are not much satisfiable. Moreover, the development of drug resistance is the major pattern observed in many targeted monotherapies. The heterogeneity of TNBC might be the cause for limited clinical benefits. Hence,, there is a need for the potential identification of new therapeutic targets to address the above limitations. In this context, some novel targets that can address the above-mentioned concerns are emerging in the era of TNBC therapy, which include Hypoxia Inducible Factor (HIF-1&#945;), Matrix Metalloproteinase 9 (MMP-9), Tumour Necrosis Factor-&#945; (TNF-&#945;), &#946;-Adrenergic Receptor (&#946;-AR), Voltage Gated Sodium Channels (VGSCs), and Cell Cycle Regulators. Currently, we summarize the ongoing clinical trials and discuss the novel therapeutic targets in the management of TNBC.]]></description> </item><item><title><![CDATA[Thyroid Metastases from Breast Cancer Case Report and Literature Review]]></title><link>https://www.benthamscience.comarticle/138712</link><description><![CDATA[<p>Background: Thyroid metastasis arising from primary breast cancer is a rare phenomenon, with only a handful of cases documented in both national and international literature. The management approach and prognosis of this occurrence have sparked debates and uncertainties. </p> <p> Case Presentation: Herein, we report the case of a 55-year-old woman with breast cancer. She previously underwent extensive excision of the breast lesion with adjuvant chemotherapy and endocrine therapy. After 9 years, she presented with neck discomfort and examination suggested right thyroid metastasis and lymph node metastasis in the neck. Imaging showed pulmonary and bone metastases. Furthermore, the patient received endocrine therapy. After 7 months of follow- up, the patient survived without any new distant metastases. Thyroid metastases originating from breast cancer often unfold with a subtle, intricate nature, making early detection challenging. They tend to emerge inconspicuously, intertwining with widespread systemic metastases, hinting at a less favorable prognosis. </p> <p> Conclusion: Given the unusual clinical indicators, identifying heterochronic thyroid metastases in patients with tumors poses a distinct challenge, requiring clinicians to navigate the follow-up process with heightened sensitivity. The key lies in timely detection and early intervention, factors that can significantly enhance the overall quality of life for patients.</p>]]></description> </item><item><title><![CDATA[An Overview of the Dichotomous Role of Microbiota in Cancer Progression and Management]]></title><link>https://www.benthamscience.comarticle/138672</link><description><![CDATA[It is a well-known fact that cancer is considered the second leading cause of mortality across the globe. Although the human oral cavity and intestine are the natural habitat of thousands of microbes, dysbiosis results in malignancies, such as oral squamous cell carcinoma and colorectal cancer. Amongst the intestinal microbes, <i>H. pylori</i> is a deadly carcinogen. Also, causative pathogens for the development of pancreatic and colorectal cancer are found in the oral cavity, such as <i>Fusobacterium nucleatum</i> and <i>Porphyromonas gingivalis</i>. Many periodontopathic micro- organisms, like <i>Streptococcus</i> sp., Peptostreptococcus sp., Prevotella sp., Fusobacterium sp., Porphyromonas gingivalis, and Capnocytophaga gingivalis, strongly have an impact on the development of oral cancers. Three basic mechanisms are involved in pathogen-mediated cancer development, like chronic inflammation-mediated angiogenesis, inhibition of cellular apoptosis, and release of carcinogenic by-products. Microbiota has a dichotomous role to play in cancer, i.e., microbiota can be used for cancer management too. Shreds of evidence are there to support the fact that microbiota enhances the chemotherapeutic drug efficacy. This review presents the possible mechanism of the oncogenic effect of microbiota with emphasis on the oral microbiome and also attempts to explain the intricate role of microbiota in cancer management.]]></description> </item><item><title><![CDATA[Targeting Epigenetic Modifiers: Promising Strategies for Cancer Therapy and Beyond]]></title><link>https://www.benthamscience.comarticle/137302</link><description><![CDATA[Epigenetic changes are important for controlling how genes are expressed and how cells work, and their misregulation has been linked to many diseases, including cancer. Targeting epigenetic modifiers has become a promising way to treat cancer, and it may also be useful outside of oncology. This review article goes into detail about the rapidly changing field of epigenetic-based therapies, with a focus on how they are used to treat cancer. We discuss in-depth the main epigenetic changes seen in cancer, such as DNA methylation, changes to histones, and dysregulation of noncoding RNA, as well as their roles in tumour growth, metastasis, and drug resistance. Epigenetic drugs and small molecule inhibitors that target epigenetic enzymes and reader proteins have shown a lot of promise in both preclinical and clinical studies on different types of cancer. We show the most recent evidence that these epigenetic therapies work and look into how they might be used in combination with other treatments. We talk about new research into the therapeutic potential of epigenetic modifiers in diseases other than cancer, such as neurological disorders, autoimmune diseases, and heart conditions. Even though there is a lot of potential for therapy, there are still problems, such as side effects and differences between patients. We talk about the work that is still being done to get around these problems and explain new ways to deliver epigenetic-based interventions that are more precise and effective. For epigenetic-based therapies to be used in clinical settings, it is important to understand how they work and how they interact with other types of treatment. As the field moves forward, we try to figure out where it is going and what it means to target epigenetic modifiers in cancer therapy and other areas of disease. This review looks at the role of epigenetic modulation in shaping the landscape of precision medicine and its possible effects on human health from a broad and forward-looking point of view.]]></description> </item><item><title><![CDATA[Malignant and Benign Head and Neck Tumors of the Pediatric Age: A Narrative Review]]></title><link>https://www.benthamscience.comarticle/137392</link><description><![CDATA[Malignant tumors of the head and neck are rare in children, but it is important to know these lesions and identify them early in order to have a good outcome for these patients. Benign lesions of the head and neck are much more frequent and have an excellent prognosis. For this reason, it is necessary to recognize the warning signs and symptoms and understand when to refer the patient to a reference center for the treatment of these pathologies. The clinical presentation of both benign and malignant lesions in children may be similar as usually, both categories have compressive effects. This confirms the fact that the clinical diagnosis is not sufficient and always requires instrumental investigations and biopsies. In this narrative review, we analyzed both malignant lesions such as lymphoma, rhabdomyosarcoma, thyroid tumors, salivary gland tumors, neuroblastoma, and nasopharyngeal carcinoma, and benign ones such as cystic dermoid teratoma, hemangioma, juvenile angiofibroma and fibrosis dysplasia. Indeed, we set out to discuss the most common lesions of this site by evaluating their characteristics to highlight the differentiation of malignant tumors from benign lesions and their correct clinical-therapeutic management. A literature search was carried out in the PubMed and Google Scholar databases to identify all narrative reviews addressing malignant and benign head and neck tumors of the pediatric age. In conclusion, the care of children affected by head and neck benign lesions and malignancy must be combined and multidisciplinary. It is essential to recognize the diseases early in order to differentiate and intervene as soon as possible for the correct clinical-therapeutic management.]]></description> </item><item><title><![CDATA[Review on Advances in Pediatric Endoscopy in the Management of Inflammatory Bowel Disease]]></title><link>https://www.benthamscience.comarticle/137673</link><description><![CDATA[Over the past decades, an increased importance has been given to gastrointestinal (GI) endoscopy in the management of children with inflammatory bowel diseases (IBD), considering that mucosal healing has been recognized as the optimal endpoint in the treat-to-target paradigm. The recent advances in technology and anesthesia have facilitated the comprehensive evaluation of the GI tract. In this review, we will discuss the role of ileocolonoscopy, upper GI endoscopy, and device-assisted enteroscopy in the work-up and management of pediatric Crohn’s disease (CD) and ulcerative colitis, with particular attention on non-invasive endoscopic techniques, such as wireless capsule endoscopy. We will also analyze the most commonly used endoscopic scoring systems, including small bowel scoring systems and endoscopic recurrence grading of neo-terminal ileum CD. Moreover, we will focus on the endoscopic management of complications, such as strictures, that commonly require surgery. Lastly, we will discuss cancer surveillance in children with IBD, with particular consideration of the role of high-definition endoscopic equipment and chromoendoscopy in dysplasia detection rates.]]></description> </item><item><title><![CDATA[Decoding the Mystery of Blood Cancer: Cause, Diagnosis, and Management]]></title><link>https://www.benthamscience.comarticle/137401</link><description><![CDATA[Leukaemia, lymphoma, and myeloma are among the serious and frequently fatal conditions that impact thousands of people each year. Genetics, environmental factors, and medical problems can all affect the risk of developing blood cancer, however, the precise causes are still not entirely known. Fatigue, unexpected weight loss, and frequent infections are examples of common blood cancer symptoms. In the course of the diagnosis process, blood tests, imaging tests, and bone marrow biopsies are frequently combined. Blood cancer therapies include chemotherapy, radiation therapy, stem cell transplant, targeted therapy, and immunotherapy. Supportive care is also important for managing symptoms and improving quality of life. Ongoing research is exploring new treatments and therapies for blood cancer, as well as ways to improve supportive care and personalize treatment plans. Blood cancer patients and their families have severe emotional and psychological effects that must not be ignored. For improving outcomes and raising the general standard of living for people affected by this condition, it is essential to address these needs.]]></description> </item><item><title><![CDATA[Therapeutic Significance of Cornin in Medicine for Their Biological Importance and Pharmacological Activity: An Overview of Iridoid Glycosides of <i>Verbena Officinalis L.</i>]]></title><link>https://www.benthamscience.comarticle/138077</link><description><![CDATA[<p>Background: Plant products have been used for the treatment of numerous kinds of human disorders since the very ancient age. Iridoid glycosides are secondary plant metabolites of medicinal importance that have been well investigated in the scientific field for their role in plants. Numerous iridoid class phytochemicals have cardiovascular, anti-viral, anti-hepatotoxic, anti-inflammatory, anti-cancer, immunomodulatory, anti-spasmodic, hypolipidemic, choleretic, purgative, and hypoglycaemic activity. </p> <p> Methods: Here in the present work, we have collected scientific information on cornin and presented it with respect to its medicinal importance and pharmacological activities with their analytical aspects. Scientific information on cornin has been collected from numerous scientific databases such as PubMed, Science Direct, Google, and Scopus to know the biological potential of cornin in medicine. Further, pharmacological activity scientific data of cornin has been presented in this work with proper citations. </p> <p> Results: The scientific data of the present paper described the biological significance of cornin in medicine. The further detailed pharmacological activity of cornin signified its therapeutic effectiveness on cerebral ischemia, angiogenesis, autophagy, myocardial injury, cerebral injury, oxidative injury, lipid peroxidation, proliferation, and cytochrome p450. Analytical data signified the separation, isolation, and identification techniques of cornin in medicine. </p> <p> Conclusion: The scientific information of the present work will be beneficial for all scientific people to explore the therapeutic effectiveness of cornin in medicine.</p>]]></description> </item><item><title><![CDATA[Mesenchymal Stem Cells Target Gastric Cancer and Deliver Epirubicin <i>via</i> Tunneling Nanotubes for Enhanced Chemotherapy]]></title><link>https://www.benthamscience.comarticle/136937</link><description><![CDATA[<p>Background: A reduced effective local concentration significantly contributes to the unsatisfactory therapeutic results of epirubicin in gastric cancer. Mesenchymal stem cells exhibit targeted chemotaxis towards solid tumors and form tunneling nanotubes with tumor cells, facilitating the delivery of various substances. This study demonstrates the novelty of mesenchymal stem cells in releasing epirubicin into gastric cancer cells through tunneling nanotubes. </p> <p> Objective: Epirubicin delivery to gastric cancer cells using mesenchymal stem cells. </p> <p> Methods: In vitro transwell migration assays, live cell tracking, and in vivo targeting assays were used to demonstrate the chemotaxis of mesenchymal stem cells towards gastric cancer. We verified the targeted chemotaxis of mesenchymal stem cells towards gastric cancer cells and the epirubicin loading ability using a high-content imaging system (Equipment type:Operetta CLS). Additionally, tunneling nanotube formation and the targeted release of epirubicin-loaded mesenchymal stem cells co-cultured with gastric cancer cells through mesenchymal stem cell-tunneling nanotubes into gastric cancer cells was observed using Operetta CLS. </p> <p> Results: Mesenchymal stem cells demonstrated targeted chemotaxis towards gastric cancer, with effective epirubicin loading and tolerance. Co-culturing induced tunneling nanotube formation between these cells. Epirubicin-loaded mesenchymal stem cells were released into gastric cancer cells through tunneling nanotubes, significantly increasing their non-viability compared to the negative control group (p &#60; 0.05). </p> <p> Conclusions: We identified a novel approach for precisely targeting epirubicin release in gastric cancer cells. Therefore, mesenchymal stem cell-tunneling nanotubes could serve as a potential tool for targeted delivery of drugs, enhancing their chemotherapeutic effects in cancer cells.</p>]]></description> </item><item><title><![CDATA[Mesenchymal Stem Cell-conditioned Medium Protecting Renal Tubular Epithelial Cells by Inhibiting Hypoxia-inducible Factor-1α and Nuclear Receptor Coactivator-1]]></title><link>https://www.benthamscience.comarticle/134759</link><description><![CDATA[<p>Background: Acute kidney injury (AKI) is characterized by inflammatory infiltration and damage and death of renal tubular epithelial cells (RTECs), in which hypoxia plays an important role. Deferoxamine (DFO) is a well-accepted chemical hypoxia-mimetic agent. Mesenchymal stem cell-conditioned medium (MSC-CM) can reduce local inflammation and repair tissue. In this study, we explored the effect and molecular mechanism of MSC-CM-mediated protection of RTECs under DFO-induced hypoxia. </p> <p> Methods: Rat renal proximal tubule NRK-52E cells were treated with different concentrations of DFO for 24 hours, followed by evaluation of RTEC injury, using a Cell Counting Kit-8 (CCK-8) to detect cell viability and western blotting to evaluate the expression of transforming growth factor- beta 1 (TGF-&#946;1), &#945;-smooth muscle actin (α-SMA), and hypoxia-inducible factor-1 alpha (HIF-1&#945;) in NRK-52E cells. Then, three groups of NRK-52E cells were used in experiments, including normal control (NC), 25 μM DFO, and 25 μM DFO + MSC-CM. MSC-CM was obtained from the human umbilical cord. MSC-CM was used to culture cells for 12 hours before DFO treatment, then fresh MSC-CM and 25 μM DFO were added, and cells were cultured for another 24 hours before analysis. </p> <p> Results: Western blotting and cellular immunofluorescence staining showed culture of NRK-52E cells in 25 μM DFO for 24 hours induced HIF-1&#945; and nuclear receptor coactivator-1 (NCoA-1), simulating hypoxia. MSC-CM could inhibit the DFO-induced up-regulation of &#945;-SMA, TGF-&#946;1, HIF-1&#945; and NCoA-1. </p> <p> Conclusion: Our results suggest that MSC-CM has a protective effect on RTECs by down-regulating HIF-1&#945; and NCoA-1, which may be the harmful factors in renal injury.</p>]]></description> </item><item><title><![CDATA[The Association between NADPH Oxidase 2 (NOX2) and Drug Resistance in Cancer]]></title><link>https://www.benthamscience.comarticle/138532</link><description><![CDATA[NADPH oxidase, as a major source of intracellular reactive oxygen species (ROS), assumes an important role in the immune response and oxidative stress response of the body. NADPH oxidase 2 (NOX2) is the first and most representative member of the NADPH oxidase family, and its effects on the development of tumor cells are gaining more and more attention. Our previous study suggested that NCF4 polymorphism in p40phox, a key subunit of NOX2, affected the outcome of diffuse large B-cell lymphoma patients treated with rituximab. It hypothesized that NOX2-mediated ROS could enhance the cytotoxic effects of some anti-tumor drugs in favor of patients with tumors. Several reviews have summarized the role of NOX2 and its congeners-mediated ROS in anti-tumor therapy, but few studies focused on the relationship between the expression of NOX2 and anti-tumor drug resistance. In this article, we systematically introduced the NOX family, represented by NOX2, and a classification of the latest inhibitors and agonists of NOX2. It will help researchers to have a more rational and objective understanding of the dual role of NOX2 in tumor drug resistance and is expected to provide new ideas for oncology treatment and overcoming drug resistance in cancer.]]></description> </item><item><title><![CDATA[The Prognostic Value and Clinical Significance of lncRNA SNHG5 Expression in Patients with Multiple Malignancies: A Bioinformatic and Meta-analysis]]></title><link>https://www.benthamscience.comarticle/138740</link><description><![CDATA[<p>Background: Long non-coding RNA small nucleolar RNA host gene 5 (lncRNA SNHG5) has been identified as both a promising target for treatment and a predictor of prognosis in diverse types of cancer. The objective of this study was to assess whether lncRNA SNHG5 expression can be utilized as a prognostic biomarker for human cancer. </p> <p> Methods: To ensure a thorough search of the literature for relevant English studies published before July 2023, several databases were searched, including PubMed, Web of Science, ProQuest, Cochrane Library, and Google Scholar. The study evaluated the impact of lncRNA SNHG5 on the overall survival (OS) of cancer by calculating the pooled hazard ratio (HR) and odds ratio (OR) with 95% confidence intervals (CIs). To further confirm the accuracy of the findings, the study investigated the expression profile and prognostic significance of lncRNA SNHG5 through the use of GenomicScape, OncoLnc, Kaplan-Meier plotter, and GEPIA databases. </p> <p> Results: In this study, 995 patients were examined across a total of fourteen original studies. The findings indicated that there was a significant relationship between heightened lncRNA SNHG5 expression and reduced OS, as evidenced by both univariate and multivariate analyses (HR = 1.89; 95% CI, 1.44-2.49; p &#60; 0.001; HR = 3.97; 95% CI, 1.80-8.73; p &#60; 0.001, respectively). Pooled OR analysis showed a significant association between over-expression of lncRNA SNHG5 with advanced histological grade (OR = 0.28; 95% CI, 0.11-0.71; p = 0.007), present lymph node metastasis (LNM; OR = 4.28; 95% CI, 2.47-7.43; p &#60; 0.001), and smoking history (OR = 0.27; 95% CI, 0.15-0.49; p &#60; 0.001). Bioinformatic databases confirmed that elevated SNHG5 expression was significantly linked to poor prognosis in cancer patients, including colorectal cancer (CRC), acute myeloid leukemia (AML), and esophageal adenocarcinoma (ESAD), and a longer OS in patients with uterine corpus endometrial carcinoma (UCEC). </p> <p> Conclusion: These results suggest that lncRNA SNHG5 may serve as an adverse prognostic biomarker in several human cancers. Further investigations are needed to better understand the underlying mechanisms that link lncRNA SNHG5 to multiple malignancies.</p>]]></description> </item><item><title><![CDATA[Curcumin and Curcumin Derivatives for Therapeutic Applications:
<i>In vitro</i> and <i>In vivo</i> Studies]]></title><link>https://www.benthamscience.comarticle/137990</link><description><![CDATA[Curcumin is a naturally derived phytochemical compound obtained from the turmeric plant <i>Curcuma longa L.</i> (Zingiberaceae family), which is a popular spice and food color and has been actively researched for decades. It has been shown to have a variety of pharmacological properties both <i>in vitro</i> and <i>in vivo</i>. Several investigations have shown that curcumin's metabolites contribute to its pharmacological effectiveness. Curcumin has potent anti-inflammatory and anti-tumor activity when used alone or in conjunction with conventional treatments. There are various unique and diverse pharmacological effects of curcumin against various disease conditions like diabetes, inflammation, cancer, malaria, and Alzheimer's. The <i>in vitro</i> and <i>in vivo</i> mechanisms by which curcumin exerts its pharmacological effects are reviewed. Based on data from the clinical and experimental evaluation of curcumin in animal models and human subjects, the review summarizes the pharmacological effect of curcumin and its derivatives concerning anti-tumor property, their mechanism of action, and their cellular target. The current research focuses on identifying curcumin's function in the immune system's cascade and determining the ideal effective dose (ED50). Through <i>in-vitro</i> and <i>in-vivo</i> experiments, the current study aims to comprehend and establish the role of curcumin in the healing of disease conditions.]]></description> </item><item><title><![CDATA[Organoids Research for Colorectal Cancer: Promising Approach for
Precision Medicine, their Applications and Future Perspectives]]></title><link>https://www.benthamscience.comarticle/134712</link><description><![CDATA[<p>Background: Organoids are three-dimensional (3D) constructs designed to emulate the complexity and functionality of organs in the body. Organoids have recently been used as powerful instruments for modeling and investigating several diseases, including colorectal cancer. Colorectal cancer is caused by altering colonic epithelial cells, which produce adenomas and carcinomas. </p> <p> Objective: The objective of present study was to investigate impact of organoids on colorectal cancer and their therapeutic outcome in cancer research. Organoids can be grown from stem cells in vitro, which closely resemble the structure and function of the organ they are derived from. They have been used in a variety of research applications, including disease modeling, drug screening, and personalized medicine. Organoids have allowed researchers to understand better the mechanisms underlying colorectal cancer initiation, progression, and resistance to therapy. </p> <p> Methods: The literature review was surveyed, and keywords related to cancer management, organoids, modelling, personized medicine, 3D structures were screened for colorectal cancer management were screened in SCI-hub, SCOPUS, WOS, and ABC Journals. </p> <p> Results: The findings of studies suggested that organoids derived from patient tumors can recapitulate the histopathology and genetic alterations of the original tumor, making them a valuable tool for personalized medicine. </p> <p> Conclusion: Organoids have been used to develop high-throughput drug screening assays and investigate the tumor microenvironment's contribution to colorectal cancer progression. In this review, we summarize recent advances in the use of organoids to study colorectal cancer and discuss their potential applications in the clinic.</p>]]></description> </item><item><title><![CDATA[Inclusive Exploration of Harmonizing and Alternative Treatments for
Hypothyroidism]]></title><link>https://www.benthamscience.comarticle/136364</link><description><![CDATA[A clinical syndrome known as hypothyroidism occurs due to a shortage of thyroid hormone as a result of decreased production, abnormal distribution, or no action of thyroid hormones. The most typical clinical symptoms included are dry skin, hair loss, weight gain, painful-prolonged periods, infertility, balance problems, slow speech, bradycardia, hypothermia, fatigue, anxiety & depression, joint pain, and indigestion. Basically, age, gender, the severity of the ailment, and a few other factors affect the various signs and symptoms of hypothyroidism. The limitations of allopathic modalities necessitate the investigation of alternative treatment options. Future healthcare initiatives for the poor world will increasingly depend on CAM approaches to these concerns because lifestyle, diet, obesity, lack of exercise, and stress are significant contributing factors to the development of hypothyroidism. This review's objective is to provide information on herbs as well as complementary and alternative medications which are grouped into five major domains: Biologically Based therapies, Manipulative body-based therapies, Mind body-based therapies, and the whole Medical system. These have traditionally been used to treat thyroid dysfunction. The distribution of diseases in emerging nations is altering as a result of globalization. Hence the existing and potential roles of CAM techniques in the general practice of medicine are illustrated in these approaches. Scientists are being compelled to consider traditional herbal medical treatments and CAM therapy in order to combat adverse medication occurrences, high treatment costs, and compliance problems thus described in this review paper.]]></description> </item><item><title><![CDATA[Angiogenesis and Pancreatic Cancer: Novel Approaches to Overcome
Treatment Resistance]]></title><link>https://www.benthamscience.comarticle/138224</link><description><![CDATA[Pancreatic cancer (PCa) is acknowledged as a significant contributor to global cancer- related mortality and is widely recognized as one of the most challenging malignant diseases to treat. Pancreatic ductal adenocarcinoma (PDAC), which is the most common type of PCa, is highly aggressive and is mostly incurable. The poor prognosis of this neoplasm is exacerbated by the prevalence of angiogenic molecules, which contribute to stromal stiffness and immune escape. PDAC overexpresses various proangiogenic proteins, including vascular endothelial growth factor (VEGF)-A, and the levels of these molecules correlate with poor prognosis and treatment resistance. Moreover, VEGF-targeting anti-angiogenesis treatments are associated with the onset of resistance due to the development of hypoxia, which in turn induces the production of angiogenic molecules. Furthermore, excessive angiogenesis is one of the hallmarks of the second most common form of PCa, namely, pancreatic neuroendocrine tumor (PNET). In this review, the role of angiogenesis regulators in promoting disease progression in PCa, and the impact of these molecules on resistance to gemcitabine and various therapies against PCa are discussed. Finally, the use of anti-angiogenic agents in combination with chemotherapy and other targeted therapeutic molecules is discussed as a novel solution to overcome current treatment limitations in PCa.]]></description> </item><item><title><![CDATA[Neuronatin Promotes the Progression of Non-small Cell Lung Cancer by
Activating the NF-&#954;B Signaling]]></title><link>https://www.benthamscience.comarticle/138189</link><description><![CDATA[<p>Background and Objectives: Understanding the regulatory mechanisms involving neuronatin (<i>NNAT</i>) in non-small cell lung cancer (NSCLC) is an ongoing challenge. This study aimed to elucidate the impact of <i>NNAT</i> knockdown on NSCLC by employing both in vitro and in vivo approaches. </p> <p> Methods: To investigate the role of <i>NNAT</i>, its expression was silenced in NSCLC cell lines A549 and H226. Subsequently, various parameters, including cell proliferation, invasion, migration, and apoptosis, were assessed. Additionally, cell-derived xenograft models were established to evaluate the effect of <i>NNAT</i> knockdown on tumor growth. The expression of key molecules, including cyclin D1, B-cell leukemia/lymphoma 2 (Bcl-2), p65, matrix metalloproteinase (MMP) 2, and nerve growth factor (NGF) were examined both <i>in vitro</i> and <i>in vivo</i>. Nerve fiber density within tumor tissues was analyzed using silver staining. </p> <p> Results: Upon <i>NNAT</i> knockdown, a remarkable reduction in NSCLC cell proliferation, invasion, and migration was observed, accompanied by elevated levels of apoptosis. Furthermore, the expression of cyclin D1, Bcl-2, MMP2, and phosphorylated p65 (p-p65) showed significant downregulation. <i>In vivo</i>, <i>NNAT</i> knockdown led to substantial inhibition of tumor growth and a concurrent decrease in cyclinD1, Bcl-2, MMP2, and p-p65 expression within tumor tissues. Importantly, <i>NNAT</i> knockdown also led to a decrease in nerve fiber density and downregulation of NGF expression within the xenograft tumor tissues. </p> <p> Conclusion: Collectively, these findings suggest that neuronatin plays a pivotal role in driving NSCLC progression, potentially through the activation of the nuclear factor-kappa B signaling cascade. Additionally, neuronatin may contribute to the modulation of tumor microenvironment innervation in NSCLC. Targeting neuronatin inhibition emerges as a promising strategy for potential anti-NSCLC therapeutic intervention.</p>]]></description> </item><item><title><![CDATA[Cancer and Autoimmune Diseases as Two Sides of Chronic Inflammation
and the Method of Therapy]]></title><link>https://www.benthamscience.comarticle/138112</link><description><![CDATA[Chronic inflammation is associated with a prolonged increase in various inflammatory factors. According to clinical data, it can be linked with both cancer and autoimmune diseases in the same patients. This raises the critical question of how chronic inflammation relates to seemingly opposing diseases - tumors, in which there is immunosuppression, and autoimmune diseases, in which there is over-activation of the immune system. In this review, we consider chronic inflammation as a prerequisite for both immune suppression and an increased likelihood of autoimmune damage. We also discuss potential disease-modifying therapies targeting chronic inflammation, which can be helpful for both cancer and autoimmunity. On the one hand, pro-inflammatory factors persisting in the areas of chronic inflammation stimulate the production of anti-inflammatory factors due to a negative feedback loop, eliciting immune suppression. On the other hand, chronic inflammation can bring the baseline immunity closer to the threshold level required for triggering an autoimmune response using the bystander activation of immune cells. Focusing on the role of chronic inflammation in cancer and autoimmune diseases may open prospects for more intensive drug discovery for chronic inflammation.]]></description> </item><item><title><![CDATA[Non-Canonical Targets of MicroRNAs: Role in Transcriptional Regulation,
Disease Pathogenesis and Potential for Therapeutic Targets]]></title><link>https://www.benthamscience.comarticle/137623</link><description><![CDATA[MicroRNAs are a class of regulatory, non-coding small ribonucleic acid (RNA) molecules found in eukaryotes. Dysregulated expression of microRNAs can lead to downregulation or upregulation of their target gene. In general, microRNAs bind with the Argonaute protein and its interacting partners to form a silencing complex. This silencing complex binds with fully or partial complementary sequences in the 3’-UTR of their cognate target mRNAs and leads to degradation of the transcripts or translational inhibition, respectively. However, recent developments point towards the ability of these microRNAs to bind to the promoters, enhancers or coding sequences, leading to upregulation of their target genes. This review briefly summarizes the various non-canonical binding sites of microRNAs and their regulatory roles in various diseased conditions.]]></description> </item><item><title><![CDATA[Unlocking the Potential of Drug Delivery Systems: A Comprehensive
Review of Formulation Strategies and Technologies in the Field of
Pharmaceutics]]></title><link>https://www.benthamscience.comarticle/136242</link><description><![CDATA[<p>The creation of innovative drug delivery systems to enhance therapeutic effectiveness, safety, and patient compliance has resulted in considerable developments in pharmaceutics in recent years. The most recent formulation techniques and technologies are reviewed in this article to improve medication distribution and accomplish specific therapeutic goals. </p> <p> This article thoroughly summarizes the most recent formulation techniques and technologies used to enhance medication delivery and provide specific therapeutic effects. It discusses the variety of medication delivery methods, including nanoparticles, liposomes, micelles, and dendrimers, and explores the application of nanotechnology and biotechnology in drug delivery. Additionally, the paper emphasizes the significance of targeted drug delivery systems and their capacity to cross biological barriers including the blood-brain barrier and tumor microenvironment. </p> <p> The review also addresses the challenges faced in developing and commercializing drug delivery systems and suggests potential solutions to overcome them. Furthermore, the article emphasizes the role of computational modeling and simulation in designing and optimizing drug delivery systems. </p> <p> Overall, this review paper offers insightful information for pharmaceutics researchers, scientists, and practitioners that will help in the creation of novel drug delivery systems that improve patient outcomes and quality of life.</p>]]></description> </item><item><title><![CDATA[Melatonin Alleviates High Glucose-induced Oxidative Stress and
Mitochondrial Dysfunction in Chondrocytes]]></title><link>https://www.benthamscience.comarticle/135907</link><description><![CDATA[<p>Background: Hyperglycemia triggers mitochondrial dysfunction in chondrocytes, potentially contributing to cell damage and the onset of osteoarthritis. </p> <p> Objective: This study is undertaken with the objective of examining the protective properties of melatonin against toxicity induced by high glucose in C28I2 human chondrocytes. </p> <p> Methods: To determine non-cytotoxic concentrations of melatonin, various concentrations (10, 25, 50, 75, 100, 500, and 1000 μM) were assessed over different time periods (24, 48, and 72 hours) for their impact on C28I2 cell viability. Following this, cells underwent a pretreatment with melatonin (10 and 100 μM) for 6 hours. This was followed by subjecting the cells to a high concentration of glucose (75 mM) for 48 hours. Oxidative stress markers, including reactive oxygen species (ROS) and malondialdehyde (MDA), alongside the enzymatic activities of glutathione peroxidase, superoxide dismutase, and catalase were quantitatively assessed. To assess mitochondrial function, we evaluated the adenosine diphosphate (ADP)/adenosine triphosphate (ATP) ratio and measured the mitochondrial membrane potential (MMP). </p> <p> Results: Elevated glucose levels significantly increased ROS and MDA levels, accompanied by reduced MMP, an elevated ADP/ATP ratio, and altered antioxidant enzyme activity. Pretreatment with melatonin effectively reversed the mitochondrial toxicity induced by high glucose (75 mM). </p> <p> Conclusion: These results indicate that melatonin exhibits a protective influence against hyperglycemia- induced toxicity in chondrocyte mitochondria.</p>]]></description> </item><item><title><![CDATA[Discovery and Development of HDAC Inhibitors: Approaches for the
Treatment of Cancer a Mini-review]]></title><link>https://www.benthamscience.comarticle/138750</link><description><![CDATA[Histone deacetylase (HDAC) inhibitors have emerged as promising cancer therapeutics due to their ability to induce differentiation, cell cycle arrest, and apoptosis in cancer cells. In the present review, we have described the systemic discovery and development of HDAC inhibitors. Researchers across the globe have identified various small molecules like benzo[d][1,3]dioxol derivatives, belinostat analogs, pyrazine derivatives, quinazolin-4-one-based derivatives, 2,4-imidazolinedione derivatives, acridine hydroxamic acid derivatives, coumarin derivatives, tetrahydroisoquinoline derivatives, thiazole-5-carboxamide, salicylamide derivatives, β-peptoid-capped HDAC inhibitors, quinazoline derivatives, benzimidazole and benzothiazole derivatives, and β- elemene scaffold containing HDAC inhibitors. Most of the scaffolds have shown attractive IC50 (μM) in various cell lines like HDAC1, HDAC2, HDAC6, PI3K, HeLa, MDA-MB-231, MCF-10A, MCF-7, U937, K562 and Bcr-Abl cell lines.]]></description> </item><item><title><![CDATA[Repurposing of Antidiarrheal Loperamide for Treating Melanoma by
Inducing Cell Apoptosis and Cell Metastasis Suppression <i>In vitro</i> and
<i>In vivo</i>]]></title><link>https://www.benthamscience.comarticle/138273</link><description><![CDATA[<p>Background: Melanoma is the most common skin tumor worldwide and still lacks effective therapeutic agents in clinical practice. Repurposing of existing drugs for clinical tumor treatment is an attractive and effective strategy. Loperamide is a commonly used anti-diarrheal drug with excellent safety profiles. However, the affection and mechanism of loperamide in melanoma remain unknown. Herein, the potential anti-melanoma effects and mechanism of loperamide were investigated <i>in vitro</i> and <i>in vivo</i>. <p> </p> Methods: In the present study, we demonstrated that loperamide possessed a strong inhibition in cell viability and proliferation in melanoma using MTT, colony formation and EUD incorporation assays. Meanwhile, xenograft tumor models were established to investigate the anti-melanoma activity of loperamide <i>in vivo</i>. Moreover, the effects of loperamide on apoptosis in melanoma cells and potential mechanisms were explored by Annexin V-FITC apoptosis detection, cell cycle, mitochondrial membrane potential assay, reactive oxygen species level detection, and apoptosis-correlation proteins analysis. Furthermore, loperamide-suppressed melanoma metastasis was studied by migration and invasion assays. What’s more, immunohistochemical and immunofluorescence staining assays were applied to demonstrate the mechanism of loperamide against melanoma <i>in vivo</i>. Finally, we performed the analysis of routine blood and blood biochemical, as well as hematoxylin- eosin (H&E) staining, in order to investigate the safety properties of loperamide. <p> </p> Results: Loperamide could observably inhibit melanoma cell proliferation <i>in vitro</i> and <i>in vivo</i>. Meanwhile, loperamide induced melanoma cell apoptosis by accumulation of the sub-G1 cells population, enhancement of reactive oxygen species level, depletion of mitochondrial membrane potential, and apoptosis-related protein activation <i>in vitro</i>. Of note, apoptosis-inducing effects were also observed in vivo. Subsequently, loperamide markedly restrained melanoma cell migration and invasion <i>in vitro</i> and <i>in vivo</i>. Ultimately, loperamide was witnessed to have an amicable safety profile. <p> </p> Conclusion: These findings suggested that repurposing of loperamide might have great potential as a novel and safe alternative strategy to cure melanoma <i>via</i> inhibiting proliferation, inducing apoptosis and cell cycle arrest, and suppressing migration and invasion.</p>]]></description> </item><item><title><![CDATA[Protective Effects of Curcumin and its Analogues <i>via</i> the Nrf2
Pathway in Metabolic Syndrome]]></title><link>https://www.benthamscience.comarticle/131672</link><description><![CDATA[<p> Metabolic Syndrome (MetS) refers to a set of medical conditions including insulin resistance, central obesity, atherogenic dyslipidemia, and hypertension. Due to these dysregulations, if not treated, MetS could increase the risk of CVA, CVD, and diabetes. As described by WHO, CVD is the leading cause of mortality in the world which motivates researchers to investigate the management of its risk factors, especially MetS. It is reported that oxidative stress secondary to the abundant generation of free radicals oxygen species (ROS) and the ensuing altered redox status play an important role as a mediator in MetS. As a result, using new antioxidant agents with higher bioavailability has been proposed as an efficient treatment. </p> <p> Curcumin (a polyphenol of the diarylheptanoids class), which is used as a traditional medicine for various diseases including cardiovascular diseases and diabetes, is characterized by its antioxidant properties which, at least in part, are mediated <i>via</i> the activation of the Nrf2/ARE signaling pathway. Nrf2 is a transcription factor that plays a key role in regulating internal defense systems and increases antioxidant levels to decrease oxidative damage and cell apoptosis. Nrf2 expression and stability are enhanced by curcumin, leading to a higher rate of Nrf2 migration to the cell nucleus to regulate ARE gene expression, thus protecting cells against oxidative stress. In this article, we provide a comprehensive review of the molecular effect of curcumin and its derivatives <i>via</i> Nrf2 regulation in several conditions, such as diabetes, hypertension, dyslipidemia, and obesity. </p>]]></description> </item><item><title><![CDATA[Unveiling the Molecular Mechanism of Diosmetin and its Impact on
Multifaceted Cellular Signaling Pathways]]></title><link>https://www.benthamscience.comarticle/139793</link><description><![CDATA[<p>Background: Diosmetin is an O-methylated flavone and the aglycone part of the flavonoid glycosides diosmin that occurs naturally in citrus fruits. Pharmacologically, diosmetin is reported to exhibit anticancer, antimicrobial, antioxidant, oestrogenic, and anti-inflammatory activities. <p> Objective: This comprehensive review was aimed to critically explore diverse pharmacological activities exhibited by diosmetin. Along with that, this review can also identify potential research areas with an elucidation of the multifactorial underlying signaling mechanism of action of diosmetin in different diseases. <p> Methods: A comprehensive collection of evidence and insights was obtained from scientific journals and books from physical libraries and electronic platforms like Google Scholar and PubMed. The time frame selected was from year 1992 to July 2023. <p> Results: The review delves into diosmetin's impact on cellular signaling pathways and its potential in various diseases. Due to its ability to modulate signaling pathways and reduce oxidative stress, it can be suggested as a potential versatile therapeutic agent for mitigating oxidative stressassociated pathogenesis. <p> Conclusion: The amalgamation of the review underscores diosmetin's promising role as a multifaceted therapeutic agent, highlighting its potential for drug development and clinical applications.</p>]]></description> </item><item><title><![CDATA[Allergic Contact Dermatitis in Pediatric Practice]]></title><link>https://www.benthamscience.comarticle/132681</link><description><![CDATA[<p>Background: Allergic contact dermatitis (ACD) is prevalent among pediatric population, adolescent and young adults. Patients with ACD experience a lot of sociopsychological and qualityof- life (QoL) difficulties. Children and their caregivers alike are vulnerable to the burden of ACD. <p> Objectives: We have, in this paper, provided an overview of ACD and discussed common and unusual causes of ACD. <p> Methods: We performed an up-to-date literature review in the English language on “allergic contact dermatitis” <i>via</i> PubMed Clinical Queries, using the keywords “allergic contact dermatitis” in August 2022. The search included meta-analyses, randomized controlled trials, clinical trials, casecontrol studies, cohort studies, observational studies, clinical guidelines, case series, case reports, and reviews. The search was restricted to English literature and children. <p> Results: ACD may be acute or chronic and it affects more than 20% of children and adults with significant quality-of-life impairments. ACD is manifested by varying degrees of cutaneous edema, vesiculation, and erythema. The hypersensitivity reaction is one of the most prevalent forms of immunotoxicity in humans. Localized acute ACD lesions can be managed with high-potency topical steroids; if ACD is severe or extensive, systemic corticosteroid therapy is often required to provide relief within 24 hours. In patients with more severe dermatitis, oral prednisone should be tapered over 2-3 weeks. Rapid discontinuation of corticosteroids can result in rebound dermatitis. Patch testing should be performed if treatment fails and the specific allergen or diagnosis remains unknown. <p> Conclusion: ACD is common and can be a physically, psychologically, and economically burdensome disease. Diagnosis of ACD is primarily based on history (exposure to an allergen) and physical examination (morphology and location of the eruption). Skin patch test can help determine the causative allergen. Allergen avoidance is the cornerstone of management. Topical mid- or highpotency corticosteroids are the mainstay of treatment for lesions on less than 20% of the body area. Severe cases of ACD may require treatment with systemic corticosteroids.</p>]]></description> </item><item><title><![CDATA[Effect of Raltitrexed on ECA109 Cellular Radiosensitivity and its Mechanism
in Esophageal Cancer]]></title><link>https://www.benthamscience.comarticle/139920</link><description><![CDATA[<p>Background: To investigate the effect of raltitrexed + X-ray irradiation on esophageal cancer ECA109 cells and analyze the potential action mechanism. <p> Methods: The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was used to analyze the inhibitory effect of raltitrexed on cell proliferation. The effect of raltitrexed on radiosensitivity was studied through a clone-forming experiment. The scratch assay and invasion test were performed to understand the cell migration and invasion abilities. The apoptosis rate change was measured using a flow cytometer, and Western Blotting was used to determine the expression of B cell lymphoma-2 (Bcl-2) and Bcl2-associated X protein (Bax) in each group. <p> Results: Raltitrexed significantly inhibited ECA109 proliferation in a time-dose-dependent manner; there were significant differences among different concentrations and times of action. The results of the clone-forming experiment showed a sensitization enhancement ratio of 1.65, and this demonstrated a radiosensitization effect. After the combination of raltitrexed with X-ray, the cell migration distance was shortened, and the number of cells penetrating the membrane was reduced. <p> Conclusion: Raltitrexed can inhibit the growth of esophageal cancer ECA109 cells and has a radiosensitization effect.</p>]]></description> </item><item><title><![CDATA[Chronic Non-bacterial Osteomyelitis (CNO) In Childhood: A Review]]></title><link>https://www.benthamscience.comarticle/127239</link><description><![CDATA[<p>Chronic non-bacterial osteomyelitis (CNO) is an autoinflammatory bone disorder mostly affecting children and adolescents. Although it is considered a rare disease, CNO is likely to be the single most common autoinflammatory bone disease in childhood, underdiagnosed and underreported due to a lack of awareness of the condition in both medics and patients and the absence of validated diagnostic criteria. The exact underlying pathogenesis of CNO remains unknown, making targeted treatment difficult. This issue is exacerbated by the lack of any randomised control trials, meaning that treatment strategies are based solely on retrospective reviews and case series. <p> This review summarises the current concepts in pathophysiology, the clinical features that help differentiate important differential diagnoses, and an approach to investigating and managing children with CNO. Ultimately, the timely and thorough investigation of children and young people with CNO is vitally important to exclude important mimics and initiate appropriate management that can prevent the complications of persistent inflammatory bone disease.</p>]]></description> </item><item><title><![CDATA[Targeted Inhibition of the PI3K/Akt/mTOR Signaling Axis: Potential for
Sarcoma Therapy]]></title><link>https://www.benthamscience.comarticle/137681</link><description><![CDATA[Sarcoma is a heterogeneous group of malignancies often resistant to conventional chemotherapy and radiation therapy. The phosphatidylinositol-3-kinase/ protein kinase B /mammalian target of rapamycin (PI3K/Akt/mTOR) signaling pathway has emerged as a critical cancer target due to its central role in regulating key cellular processes such as cell growth, proliferation, survival, and metabolism. Dysregulation of this pathway has been implicated in the development and progression of bone sarcomas (BS) and soft tissue sarcomas (STS). PI3K/Akt/mTOR inhibitors have shown promising preclinical and clinical activity in various cancers. These agents can inhibit the activation of PI3K, Akt, and mTOR, thereby reducing the downstream signaling events that promote tumor growth and survival. In addition, PI3K/Akt/mTOR inhibitors have been shown to enhance the efficacy of other anticancer therapies, such as chemotherapy and radiation therapy. The different types of PI3K/Akt/mTOR inhibitors vary in their specificity, potency, and side effect profiles and may be effective depending on the specific sarcoma type and stage. The molecular targeting of PI3K/Akt/mToR pathway using drugs, phytochemicals, nanomaterials (NMs), and microbe-derived molecules as Pan-PI3K inhibitors, selective PI3K inhibitors, and dual PI3K/mTOR inhibitors have been delineated. While there are still challenges to be addressed, the preclinical and clinical evidence suggests that these inhibitors may significantly improve patient outcomes. Further research is needed to understand the potential of these inhibitors as sarcoma therapeutics and to continue developing more selective and effective agents to meet the clinical needs of sarcoma patients.]]></description> </item><item><title><![CDATA[Treatment Advances in Lung Cancer with Leptomeningeal Metastasis]]></title><link>https://www.benthamscience.comarticle/137788</link><description><![CDATA[<p>Leptomeningeal metastasis (LM) is a serious and often fatal complication in patients with advanced lung cancer, resulting in significant neurological deficits, decreased quality of life, and a poor prognosis. <p> This article summarizes current research advances in treating lung cancer with meningeal metastases, discusses clinical challenges, and explores treatment strategies. <p> Through an extensive review of relevant clinical trial reports and screening of recent conference abstracts, we collected clinical data on treating patients with lung cancer with meningeal metastases to provide an overview of the current research progress. <p> Exciting progress has been made by focusing on specific mutations within lung cancer, including the use of EGFR tyrosine kinase inhibitors or inhibitors for anaplastic lymphoma kinase gene rearrangement, such as osimertinib, alectinib, and lorlatinib. These targeted therapies have shown impressive results in penetrating the central nervous system (CNS). Regarding whole-brain radiotherapy, there is currently some controversy among investigators regarding its effect on survival. Additionally, immune checkpoint inhibitors (ICIs) have demonstrated reliable clinical benefits due to their ability to retain anticancer activity in CNS metastases. Moreover, combination therapy shows promise in providing further treatment possibilities. <p> Considerable progress has been made in the clinical research of lung cancer with LM. However, the sample size of prospective clinical trials investigating LM for lung cancer is still limited, with most reports being retrospective. Developing more effective management protocols for metastatic LM in lung cancer remains an ongoing challenge for the future.</p>]]></description> </item><item><title><![CDATA[Diverse Pharmacological Potential of different Substituted Pyrazole
Derivatives]]></title><link>https://www.benthamscience.comarticle/135192</link><description><![CDATA[The chemistry of heterocyclic compounds has been a topic of research interest. Some five-membered heterocyclic compounds have been the subject of extensive research due to their different types of pharmacological effects. The five-membered nitrogen-containing heterocyclic compounds pyrazole, pyrazoline, and pyrazolone derivatives have a lot of interest in the fields of medical and agricultural chemistry due to their diverse spectrum of therapeutic activities. Various substituted pyrazole, pyrazoline, and pyrazolone compounds exhibited diverse pharmacological effects like Anti-microbial, anti-inflammatory, anti-tubercular, anti-fungal, anti-malarial, anti-diabetic, diuretic, anti-depressant, anticonvulsant, antioxidant, anti-leishmanial, antidiabetic, and antiviral, etc. In recent decades, the synthesis of numerous pyrazole, pyrazoline, and pyrazolone derivatives by different synthetic methods as well as research into their chemical and biological behavior have become more important. This review focuses on synthetic methods of the pyrazole, pyrazoline, and pyrazolone derivatives, which have significant biological properties and a variety of applications.]]></description> </item><item><title><![CDATA[A Review on Anaplastic Lymphoma Kinase (ALK) Rearrangements and
Mutations: Implications for Gastric Carcinogenesis and Target Therapy]]></title><link>https://www.benthamscience.comarticle/138845</link><description><![CDATA[Gastric adenocarcinoma is a complex disease with diverse genetic modifications, including Anaplastic Lymphoma Kinase (ALK) gene changes. The ALK gene is located on chromosome 2p23 and encodes a receptor tyrosine kinase that plays a crucial role in embryonic development and cellular differentiation. ALK alterations can result from gene fusion, mutation, amplification, or overexpression in gastric adenocarcinoma. Fusion occurs when the ALK gene fuses with another gene, resulting in a chimeric protein with constitutive kinase activity and promoting oncogenesis. ALK mutations are less common but can also result in the activation of ALK signaling pathways. Targeted therapies for ALK variations in gastric adenocarcinoma have been developed, including ALK inhibitors that have shown promising results in pre-clinical studies. Future studies are needed to elucidate the ALK role in gastric cancer and to identify predictive biomarkers to improve patient selection for targeted therapy. Overall, ALK alterations are a relevant biomarker for gastric adenocarcinoma treatment and targeted therapies for ALK may improve patients' overall survival.]]></description> </item><item><title><![CDATA[A Novel Electrochemiluminescence (ECL) Immunoassay for the Quantitation
of Monoclonal Antibody (mAb) PYX-106 in Human Serum]]></title><link>https://www.benthamscience.comarticle/139390</link><description><![CDATA[<p>Background: PYX-106 is a novel monoclonal antibody (mAb), targeting the sialic acidbinding immunoglobulin-like lectin 15 (Siglec-15) in the Tumor Microenvironment (TME). Precise measurement of PYX-106 is essential for the thorough assessment of PYX-106 pharmacokinetics in clinical investigations. <p> Methods: A novel Electrochemiluminescence (ECL) immunoassay for the quantitation of PYX- 106 in human serum was developed and validated. Biotinylated anti-PYX-106 antibody Bio-A1A1 was employed as the capture antibody, and ruthenylated anti-PYX-106 antibody Ru-A3G10 was utilized as the detection antibody in the ECL immunoassay on Meso Scale Discovery (MSD) platform. <p> Results: This assay was fully validated in terms of selectivity, accuracy, precision, hook effect, stability, etc., with a dynamic range from 50.0 to 2,500 ng/mL in human serum under the 2018 U.S. Food and Drug Administration (FDA) guidance and the 2022 U.S. FDA ICH M10 guidance. <p> Conclusion: PYX-106 bioanalytical assay validation was reported for the first time in a biological matrix, and this assay has been successfully applied to support a clinical trial PYX-106-101.</p>]]></description> </item><item><title><![CDATA[DHFS-ECM: Design of a Dual Heuristic Feature Selection-based Ensemble
Classification Model for the Identification of Bamboo Species from
Genomic Sequences]]></title><link>https://www.benthamscience.comarticle/138279</link><description><![CDATA[<P>Background: Analyzing genomic sequences plays a crucial role in understanding biological diversity and classifying Bamboo species. Existing methods for genomic sequence analysis suffer from limitations such as complexity, low accuracy, and the need for constant reconfiguration in response to evolving genomic datasets. <P> Aim: This study addresses these limitations by introducing a novel Dual Heuristic Feature Selection- based Ensemble Classification Model (DHFS-ECM) for the precise identification of Bamboo species from genomic sequences. <P> Methods: The proposed DHFS-ECM method employs a Genetic Algorithm to perform dual heuristic feature selection. This process maximizes inter-class variance, leading to the selection of informative N-gram feature sets. Subsequently, intra-class variance levels are used to create optimal training and validation sets, ensuring comprehensive coverage of class-specific features. The selected features are then processed through an ensemble classification layer, combining multiple stratification models for species-specific categorization. <P> Results: Comparative analysis with state-of-the-art methods demonstrate that DHFS-ECM achieves remarkable improvements in accuracy (9.5%), precision (5.9%), recall (8.5%), and AUC performance (4.5%). Importantly, the model maintains its performance even with an increased number of species classes due to the continuous learning facilitated by the Dual Heuristic Genetic Algorithm Model. <P> Conclusion: DHFS-ECM offers several key advantages, including efficient feature extraction, reduced model complexity, enhanced interpretability, and increased robustness and accuracy through the ensemble classification layer. These attributes make DHFS-ECM a promising tool for real-time clinical applications and a valuable contribution to the field of genomic sequence analysis.</P>]]></description> </item><item><title><![CDATA[SMAC Mimetics for the Treatment of Lung Carcinoma: Present
Development and Future Prospects]]></title><link>https://www.benthamscience.comarticle/137731</link><description><![CDATA[<P>Background: Uncontrolled cell growth and proliferation, which originate from lung tissue often lead to lung carcinoma and are more likely due to smoking as well as inhaled environmental toxins. It is widely recognized that tumour cells evade the ability of natural programmed death (apoptosis) and facilitates tumour progression and metastasis. Therefore investigating and targeting the apoptosis pathway is being utilized as one of the best approaches for decades. <P> Objective: This review describes the emergence of SMAC mimetic drugs as a treatment approach, its possibilities to synergize the response along with current limitations as well as future perspective therapy for lung cancer. <P> Method: Articles were analysed using search engines and databases namely Pubmed and Scopus. <P> Result: Under cancerous circumstances, the level of Inhibitor of Apoptosis Proteins (IAPs) gets elevated, which suppresses the pathway of programmed cell death, plus supports the proliferation of lung cancer. As it is a major apoptosis regulator, natural drugs that imitate the IAP antagonistic response like SMAC mimetic agents/Diablo have been identified to trigger cell death. SMAC i.e. second mitochondria activators of caspases is a molecule produced by mitochondria, stimulates apoptosis by neutralizing/inhibiting IAP and prevents its potential responsible for the activation of caspases. Various preclinical data have proven that these agents elicit the death of lung tumour cells. Apart from inducing apoptosis, these also sensitize the cancer cells toward other effective anticancer approaches like chemo, radio, or immunotherapies. There are many SMAC mimetic agents such as birinapant, BV-6, LCL161, and JP 1201, which have been identified for diagnosis as well as treatment purposes in lung cancer and are also under clinical investigation. <P> Conclusion: SMAC mimetics acts in a restorative way in the prevention of lung cancer.</P>]]></description> </item><item><title><![CDATA[Drug Delivery Systems based on Microneedles for Dermatological
Diseases and Aesthetic Enhancement]]></title><link>https://www.benthamscience.comarticle/132065</link><description><![CDATA[Microneedle (MN) devices comprise of micron-sized structures that circumvent biological barriers in a minimally invasive manner. MN research continues to grow and evolve; the technology was recently identified as one of the top ten overall emerging technologies of 2020. There is a growing interest in using such devices in cosmetology and dermatological conditions where the MNs mechanically disrupt the outer skin barrier layer, creating transient pathways that allow the passage of materials to underlying skin layers. This review aims to appraise the application of microneedle technologies in skin science, provide information on potential clinical benefits, as well as indicate possible dermatological conditions that can benefit from this technology, including autoimmunemediated inflammatory skin diseases, skin aging, hyperpigmentation, and skin tumors. A literature review was carried out to select studies that evaluated the use of microneedles to enhance drug delivery for dermatologic purposes. MN patches create temporary pathways that allow the passage of therapeutic material to deeper layers of the skin. Given their demonstrable promise in therapeutic applications it will be essential for healthcare professionals to engage with these new delivery systems as they transition to the clinic.]]></description> </item><item><title><![CDATA[The Chemoprotective Potentials of Alpha-lipoic Acid against
Cisplatin-induced Ototoxicity: A Systematic Review]]></title><link>https://www.benthamscience.comarticle/131664</link><description><![CDATA[<p> Purpose: Ototoxicity is one of the major adverse effects of cisplatin therapy which restrict its clinical application. Alpha-lipoic acid administration may mitigate cisplatin-induced ototoxicity. In the present study, we reviewed the protective potentials of alpha-lipoic acid against the cisplatin-mediated ototoxic adverse effects. <p> Methods: Based on the PRISMA guideline, we performed a systematic search for the identification of all relevant studies in various electronic databases up to June 2022. According to the inclusion and exclusion criteria, the obtained articles (n=59) were screened and 13 eligible articles were finally included in the present study. <p> Results: The findings of <i>in-vitro</i> experiments showed that cisplatin treatment significantly reduced the auditory cell viability in comparison with the control group; nevertheless, the alpha-lipoic acid co-administration protected the cells against the reduction of cell viability induced by cisplatin treatment. Moreover, the <i>in-vivo</i> results of the auditory brainstem response (ABR) and distortion product otoacoustic emission (DPOAE) tests revealed a decrease in DPOAE and an increase in ABR threshold of cisplatin-injected animals; however, it was shown that alpha-lipoic acid co-treatment had an opposite pattern on the evaluated parameters. Other findings demonstrated that cisplatin treatment could significantly induce the biochemical and histopathological alterations in inner ear cells/tissue; in contrast, alpha-lipoic acid co-treatment ameliorated the cisplatin-mediated biochemical and histological changes. <p> Conclusion: The findings of audiometry, biochemical parameters, and histological evaluation showed that alpha-lipoic acid co-administration alleviates the cisplatin-induced ototoxicity. The protective role of alpha-lipoic acid against the cisplatin-induced ototoxicity can be due to different mechanisms of anti-oxidant, anti-apoptotic, anti-inflammatory activities, and regulation of cell cycle progression.</p>]]></description> </item><item><title><![CDATA[An Updated Review on the Significance of DNA and Protein
Methyltransferases and De-methylases in Human Diseases: From
Molecular Mechanism to Novel Therapeutic Approaches]]></title><link>https://www.benthamscience.comarticle/132369</link><description><![CDATA[Epigenetic mechanisms are crucial in regulating gene expression. These mechanisms include DNA methylation and histone modifications, like methylation, acetylation, and phosphorylation. DNA methylation is associated with gene expression suppression; however, histone methylation can stimulate or repress gene expression depending on the methylation pattern of lysine or arginine residues on histones. These modifications are key factors in mediating the environmental effect on gene expression regulation. Therefore, their aberrant activity is associated with the development of various diseases. The current study aimed to review the significance of DNA and histone methyltransferases and demethylases in developing various conditions, like cardiovascular diseases, myopathies, diabetes, obesity, osteoporosis, cancer, aging, and central nervous system conditions. A better understanding of the epigenetic roles in developing diseases can pave the way for developing novel therapeutic approaches for affected patients.]]></description> </item></channel></rss>